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Summary
Prostate cancer is the second most common cancer among men. The prostate
specific antigen (PSA) was the first biomarker identified for the diagnosis of this
prevalent disease. Although this biomarker is in routine use it has been extensively
criticised and discredited due to the large number of false positives identified
from its usage, which result from benign conditions such as benign prostatic
hyperplasia and prostatitis. Several studies have therefore made use of genomic,
transcriptomic and proteomic methods to identify novel candidate biomarkers for
prostate cancer, which can replace PSA. The aim of this study was to contribute
to this search by using state-of-the-art mass spectrometry based proteomics to
characterise the proteome and secretome of benign (BPH-1), cancerous (LNCaP
and PC-3) and normal (PNT2C2) prostate cell lines. The seeding densities of
the four prostate cell lines were optimised for maximum protein secretion and
reduced cell death in a chemically defined medium, with lower seeding densities
yielding the best results. Acetone precipitation was subsequently found to yield the
best protein recoveries from the conditioned media when compared to three other
methods, which included ammonium sulphate, methanol chloroform and PTA-
mediated acetone precipitation. The proteome and secretome profiles of the four
cell lines were subsequently characterised by mass spectrometer based proteomics.
A total of 3576 and 1106 proteins were positively assigned from the proteome
and secretome samples, respectively. This data was subsequently analysed using
Ingenuity Pathway Analysis, several upregulated molecular pathways, upstream
regulators, molecular and cellular processes, disease states and potential biomarkers
were identified. The data showed that pathways involved in the regulation of a
Adherens junctions, oxidative phosphorylation and mitochondria were significantly
upregulated in the prostate cancer cell lines and may therefore be useful avenues to
pursue when searching for candidate biomarkers or therapeutic targets for prostate
cancer. Furthermore, a total of 157 candidate biomarkers which could distinguish
the prostate cancer cell lines from the benign prostatic hyperplasia cell line were
identified. Despite a number of limitations this study further demonstrates the use
of secretome based proteomics as a tool to complement biomarker discovery.
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Opsomming
Prostaatkanker is die tweede mees algemene kanker onder mans. Die prostaat-
spesifieke antigeen (PSA) was die eerste biomerker gëıdentifiseer vir die diagnose
van hierdie algemene siekte. Alhoewel hierdie biomerker in roetinegebruik is, is
dit gekritiseer en gediskrediteer as ’n biomarker vir prostaatkanker as gevolg van
die groot aantal vals positiewes wat gëıdentifiseer is met die gebruik daarvan, wat
as gevolg van toestande soos nie-kwaadaardige prostaat hiperplasie en prostatitis
is. Verskeie studies het dus gebruik gemaak van genomiese, transkriptomiese en
proteomiese metodes om nuwe kandidaat biomerkers vir prostaatkanker, wat PSA
kan vervang, te identifiseer. Die doel van hierdie studie was om by te dra tot
hierdie soektog deur die gebruik van massaspektrometrie-gebaseerde proteomika.
Die proteoom en secretoom van nie-kwaadaardige (BPH-1), kanker (LNCaP en
PC-3) en normale (PNT2C2) prostaat sellyn was ontleed. Die lotingdigthede van
die vier prostaat sellyne is geoptimiseer vir maksimum protëıen sekresie en minimale
seldood. ’n Laer lotingdigthede het die beste resultate gelewer. Asetoonpresipitasie
het die beste protëıenherwinning van die gekondisioneerde media gelewer. Die
ander metodes wat getoets was, was die ammoniumsulfaat, metanol chloroform en
PTA-bemiddelde asetoonpresipitasie metodes. Die proteoom en secretoom profiele
van die vier sellyne is daarna met behulp van massaspektrometer bemiddelde pro-
teomika ontleed. ’n Totaal van 3576 en 1106 protëıene is positief uit die proteoom
en secretome monsters onderskeidelik, gëıdentifiseer. Hierdie data is verder ontleed
met behulp van “Ingenuity Pathway Analysis” sagteware. Verskeie veranderinge
in molekuêre paaie, stroomop reguleerders, molekuêre en sellulêre prosesse, siek-
tetoestande en potensile biomerkers is gëıdentifiseer. Die data het getoon dat
paaie wat betrokke is by die regulering van ’n Adherens aansluitings, oksidatiewe
fosforilering en mitochondria is opgereguleer in die prostaatkanker sellyne en is
dus nuttig paaie om te ondersoek vir kandidaatbiomerkers of terapeutiese middels
vir prostaatkanker. Verder is ’n totaal van 157 kandidate biomerkers wat die
prostaatkanker sel lyne van die nie-kwaadaardige prostaat hiperplasie sellyn kan
onderskei, gëıdentifiseer. Ten spyte van ’n aantal beperkings in hierdie studie toon
die resultate dat sekretoom-gebaseerde proteomika gebruik kan word om biomerker
ontdekking aan te vul.
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Chapter 1
An introduction to prostate
cancer and biomarkers
1.1 Cancer
1.1.1 Cancer fact sheet
Cancer is one of the leading causes of non-communicable deaths worldwide.1
Cancer is the collective term for a group of neoplasmic diseases characterised by
the uncontrolled proliferation of cells with the ability to invade surrounding tissue
or to metastasise.2 This is in contrast to benign tumours which also result from
the uncontrolled proliferation of cells, but lack these characteristics and are thus
considered non-cancerous.3
Cancers can further be differentiated into five classes based on their origin:
carcinomas (epithelial), sarcomas (connective tissue), lymphomas (blood or lymph),
germ cells (pluripotent) and blastomas (embryonic).4 Carcinomas are those that
originate from epithelial tissues and account for more than 90% of all cancers.3
Common carcinomas include prostate, colon, breast and lung cancers.3 These
cancers are usually age or environmentally related and are classic late onset cancers.3
Sarcomas originate from mesenchymal tissues such as bone, connective tissue and
cartilage and are prevalent in adults but occur at a higher rate in children.5
Lymphomas originate in blood or lymph and include Hodgkin’s and non-Hodgkin’s
lymphoma.6 Germ cell cancers occur in the germ cells and are usually the result of
birth defects or problems occurring during embryonic development.7 Blastomas
occur as a result of malignancies in precursor cells usually as a result embryonic
developmental errors.8
Hormone dependent cancers are dependent on specific sex hormones and include
breast, cervical, uterine, endometrial, testicle and prostate cancers.9 The sex
hormones are divided into androgens, oestrogens and progestogens which are all
1
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1.1. CANCER 2
steroid hormones produced in the gonads as well as in the adrenal glands, albeit
in lower quantities.10 Research has also shown that the presence of exogenous
hormones from foods, contraceptives and hormone replacement therapies has
exacerbated the incidence of hormone dependent cancers.9
While cancers may have many origins they all share the same traits, namely:
unregulated cell proliferation caused by an increase in pro-proliferation signals or
the reduction in anti-proliferation signals; the decreased production of suppressor
genes; the reduction in controlled apoptosis; limitless proliferation potential; the
ability to stimulate construction of blood vessels; the ability to invade tissues; and
the ability to spread or metastasise.11
While cancer is generally attributed to the uncontrolled proliferation of cells
and the development of tumours in most cases there are little to no early overt
symptomatic traits that allude to its specific occurrence.12 The non-specific nature
of cancer means it often goes undetected or is misdiagnosed in patients until more
severe symptoms require closer evaluation.13 The development of tumours in or
around specific organs do eventually indicate a disease state.14 For instance in
the case of lung cancer patients may present with a non-specific cough15 and in
the case of prostate cancer urinary incontinence.16 These symptoms necessitate
further testing which often leads to diagnosis. Currently large amounts of research
is focused on better identifying the symptomatic traits that may aid in the early
diagnosis of cancer.17,18
1.1.2 Global prevalence
Currently there are over 100 types of cancer globally with incidences and mortalities
specific to certain regions often correlated to the human development index (HDI)
status of the area.19 The development index has direct correlation to quality
of life and subsequent lifestyle traits.19 Factors of the HDI that contribute to
cancer incidence and mortality include: age, drug use, diet, obesity, exposure to
cancer causing agents (carcinogens), cancer causing infections and genetic risk
factors.19 Cancer is the leading cause of mortality in countries with high to very
high development indices while, cancer is second to communicable diseases in
countries with medium and low development indices as seen in figure 1.1.20 That
being said non-communicable diseases are steadily becoming more and more of a
burden on countries with a low to medium HDI.21 In 2012 there was an incidence of
14.1 million cases of cancer globally resulting in 8.2 million deaths and accounting
for 14.6% of the total deaths recorded that year.1 While incidence in high to very
high HDI was higher (56%) compared to low to medium HDI countries (44%) the
mortality rates were higher in low to medium HDI countries (53%).19 This can be
attributed to the availability of treatment in these countries.22 Certain cancers are
more prevalent globally than other cancers with lung, breast, colorectal, prostate
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and stomach cancers contributing to over 49% of the overall cancers.23 The most
common cancer in women is breast cancer (25.2%), while lung cancer (16.7%) is
the most common cancer in men with prostate cancer coming a close second at
14.8%.22,23
The global cost of cancer places large burdens on economies not only from a
treatment perspective but loss of incomes due to loss of life and was estimated to
cost the global market 1.16 trillion US dollars in 2010.1
Figure 1.1: The global prevalence of all cancers (excluding non-melanoma skin
cancer). Incidence is greatly increased in countries with high HDI compared to
countries with low to medium HDI. Incidence was recorded as 5 year prevalence
proportions per 100 000. Reproduced from GLOBOCAN 2012 (IARC).19
1.2 The prostate
The prostate is a small, internal, compound exocrine gland found in men located
below the bladder on the anterior side of the rectum.24 Its size and weight is
dependent on overall body mass index of the individual but is usually referred to as
walnut sized (3 cm long, 4 cm wide, 2 cm thick) weighing on average 20 grams.25
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1.2. THE PROSTATE 4
1.2.1 Prostate morphology
The prostate is a complex set of glands made up of distinct regions.26 These regions
were originally characterised anatomically as a set of four connected lobes including:
the anterior lobe (isthmus), posterior lobe, median lobe or middle lobe and lateral
lobes.27 The prostate is now better characterised into three distinct glandular zones:
the transition zone, the central zone and the peripheral zone as well as the anterior
fibromuscular stroma as seen in figure 1.2.28–30 The innermost transition zone
directly surrounds the proximal urethra and accounts for 5-10% (5% at puberty)
of the prostate.26,30 It separates the bladder from the membranous urethra and is
made up of pseudostratified columnar epithelium and secretory cells.25,29 It is the
only part of the gland that grows throughout a males lifetime and thus results in
late onset urinary conditions such as benign prostatic hyperplasia (BPH).31 The
central zone is anterior to the transition zone and surrounds the ejaculatory ducts
and makes up 25% of the prostate.26,30 The central zone contributes to 2.5% of
cancers that are considered to be more aggressive and invasive than cancers that
affect other regions of the prostate.32,33 The peripheral zone is posterior to the
transition zone and makes up 70% of the prostate.26,30 The peripheral zone forms
the sub-capsular portion and surrounds the distal urethra of the prostate32 and is
the site of most prostate cancers.34 The anterior fibromuscular stroma contains
no glandular components and composed of muscle and fibrous tissue and extends
between the urethra and transition zone.35
The prostate does not have a true capsule but is supported by randomly
orientated fibromuscular stroma bundles.35 The muscular component condenses
peripherally to form the prostatic sheath and centrally merges into the muscle
layers of the prostatic urethra.36
The prostate contains multiple gland types made up of various tissues.25 The
tubuloalveolar glands have pseudostratified columnar epithelium that vary in
height.25 The columnar cells, separated by basal cells contain apical secretory
granules, while the basal cells are responsible for epithelium regeneration.25 The
prostate contains branching secretory tubules and acini that are surrounded by
fibromuscular stroma.37 In total the stroma accounts for about 70% of the prostate
mass.25
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Figure 1.2: The relative location and zonal morphology of the prostate. The prostate
contains the central zone, transitional zone and the peripheral zone surrounded by
a fibromuscular stroma. Panel A depicts the sagittal view and panel B depicts the
axial view with the top, middle and bottom sections depicting the base, mid gland
and apex respectively. Reproduced from http://clinicalgate.com/prostate-cancer-
4/.
1.2.2 Prostate function
The prostate is common among mammals and is referred to as an accessory sex
gland.25 It is not a critical part of the male reproductive but aids in fertility and
urinary systems producing and combing constituents of seminal fluid and physical
control of the urinary system.38
The central zone links the ductus deferens to the ejaculatory tubes and drains
into the urethra.32 This is the common site where the semen, fluid from the seminal
vesicles and secretions from the bulbourethral gland are combined.38 The prostate
provides a variety of ions, lipids, simple sugars and a small portion of proteins
(1%) to the ejaculate.39 Some of these proteins include: proteolytic enzymes,
prostatic acid phosphatase, beta-microseminoprotein and the prostate-specific
antigen (PSA).39,40
PSA is produced by the secretory epithelium of the prostate and is responsible
for the liquefaction of semen through the cleaving of semenogelin that increasing
motility.41,42 Upon damage to basal membrane and basal epithelial layer PSA leaks
through the basal cells into the stroma and vasculature.41,42 Serum PSA is thus
elevated in patients presenting with prostate cancer and other prostatic conditions
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such as BPH and prostatitis.41,42 PSA is therefore widely used as a biomarker.40
The prostate also contains various muscular structures that are required to force
ejaculate out of the urethra as well as prevent flow of urine into the seminal system.38
The prostate and bladder sphincters work together to regulate the flow of urine and
semen.38 During ejaculation the internal sphincter closes to the bladder preventing
flow black of semen into the bladder.38 Alternatively during urination the seminal
ducts close to prevent urine from entering the seminal system.38 The prostate
utilises smooth muscle fibres that help expel the fluid during ejaculation.25 During
ejaculation the prostatic acini are compressed by the surrounding fibromuscular
coat that empties their components into the posterior urethra.43
1.2.3 Prostate development and maintenance
The development and maintenance of the prostate requires nutrients, oxygen and
androgens (male sex hormones), which control the balance of proliferation and
apoptosis.44 The most important of these hormones is the androgen testosterone
that is produced in the Leydig cells of the testes.45 Testosterone production is dually
regulated by luteinizing hormone and luteinizing hormone releasing hormone.46
Androgens such as testosterone and its more potent form dihydrotestosterone (DHT)
act by the ligand dependent transcription factor, known as the androgen receptor
(AR) which is part of the nuclear receptor family and has multiple signalling
mechanisms.47
The unliganded AR is located in the cytoplasm and is bound to heat shock
protein 70 and heat shock protein 90.48 Upon ligand binding these dissociate and
the AR forms a homodimer which rapidly translocates into the nucleus where the
liganded complex binds to specific DNA sequences known as androgen response
elements (AREs).48 The subsequent binding of cofactors allows the regulation of
AR regulated genes such as PSA.48
Loss of AR activation leads to low prostatic development and prostate tissue
atrophy, while the subsequent re-introduction of androgens leads to tissue regenera-
tion, growth and secretory function.49 Patients presenting with steroid 5α-reductase
(SRD5A) deficiencies resulted in atrophied prostate tissue.49–51 SRD5A is respons-
ible for the conversion of testosterone into the more potent androgen DHT required
for normal prostate function.52
1.2.4 Prostatic conditions
The prostate is highly susceptible to inflammatory diseases such as BPH and
prostatitis which usually occur later in life.52 Prostatitis is the inflammation of the
prostate caused by increased age or bacterial infection.53 It can take four forms
including the rarer acute or chronic bacterial form that is treated using antibiotics
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or the more common non-bacterial or chronic pelvic pain syndrome treated using
antibiotics and surgical reduction.53
BPH is the enlargement of the prostate that leads to the progressive blocking of
the urethra that can impair adequate urinary function.54 This is often treated using
medication or more complex surgical means.54 BPH is considered unavoidable and
prevention is currently being investigated but it has been shown that that changes
in diet and moderate intake of alcohol may have a beneficial effect.55 BPH is highly
prevalent occurring in 88% of men over the age of 8056,57 and readily treatable56,57
whereas prostate cancer (PCa) is less prevalent but far more deadly.58
1.3 Prostate cancer
PCa is the 2nd most common cause of cancer internationally accounting for 14.8%
of male cancer diagnosis annually.23 As of 2016 over one million men23 are living
with prostate cancer and a further 180 000 will be diagnosed in the USA alone.59
PCa has a fairly large mortality rate of 6.6%23 with over 26 000 deaths estimated
for 2016 in the USA.59 It is more prevalent in high HDI countries but is rapidly
increasing in low to middle HDI countries19 attributed to of better and more regular
screening techniques.60 PCa is the most common cancer among South African men,
accounting for 17.15% of cancers annually and carrying a lifetime risk of 1 in 27.61
1.3.1 Prostate cancer risk factors
PCa usually doesn’t occur as a result of one specific cause but instead it is attributed
to the accumulation of genetic errors exacerbated by age, ethnicity, genetics, lifestyle
and diet.62 Age is by far the biggest risk factor when considering PCa incidence62
with the risk steadily increasing from 0.6% in men aged 35-44 to 37.6% in men aged
65-74 with the median age of diagnosis being 66 years of age.59 Ethnicity also plays
a large role with prostate cancer being more prevalent in white males61 but the
associated risk being higher in black males.62 This has been attributed to genetic
as well as lifestyle factors exemplified by the increase in PCa prevalence in African
Americans who have immigrated to HDI countries like the USA.62 Genetics of PCa
are still not fully elucidated but it has been shown that the incidence of prostate
increases substantially in families with a history of PCa.63 If a close relative such
as a father or brother is diagnosed with PCa the risk of being diagnosed with
PCa increases by a factor of 2.35 and 3.14 respectively.62 Lifestyle factors such
as smoking, lack of physical activity, obesity and alcohol intake have been shown
to increase the risk of prostate cancer.61 Diet and its effect on PCa has been
comprehensively studied and has yielded confounding results possibly implicating,
high fat, high red meat, low vegetable diets in increasing the risk of PCa.61 PCa is
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not readily preventable, but lifestyle changes such as diet changes, avoiding tobacco,
low alcohol intake and avoiding other carcinogens may significantly reduce the
likelihood of PCa64
1.3.2 Development of prostate cancer
The development and progression of PCa is complex and poorly understood.65
Multiple pathways and mechanisms have been proposed building on historical,
histological and genetic data.66 Recent evidence has implicated precancerous con-
ditions in the initiation and progression of PCa.66 Large amounts of evidence have
implicated prostatic intraepithelial neoplasia (PIN) that is preceded by proliferative
inflammatory atrophy as an intermediate in the development of PCa.66
PIN is characterised by a number of lesions forming on the prostate classified
according to their overall morphology including: cribriform, flat, micropapilary
and tufting.66 PIN can either occur as low-grade (LGPIN) or high-grade (HGPIN)
depending on the extent of the lesions.66 It has been hypothesised that HGPIN
may be the immediate precursor to PCa due to a number of shared commonalities
with PCa such as: HGPIN occurring in the transition zone; HGPIN diagnosis
preceding PCa diagnosis by ten years, multiple similar genetic changes; similar mor-
phologies; similar altered differentiation factors and increased telomerase activity.66
Furthermore, PIN has been shown not to be precursor of other prostatic conditions
such as BPH and prostatitis.66 While HGPIN is similar to PCa it does not result
in degradation of the basement membrane or increase the abundance of PSA.66
Advanced PCa can metastasise rapidly and move from the prostate to surrounding
tissue.67 The final location is regulated by the distant microenvironment and
chemokine gradients67 and PCa preferentially migrates to bone, lung and liver68
tissue utilising lymphatic, haematogenous and contiguous local spread.69
1.3.3 Genetic changes in prostate cancer
While it is easy to think that all tumours possess the same mutations and that
these all occur at the same time, this is not the case and multiple different types of
tumour mutations and tumour mutation profiles exist and interact to compound the
effect of loss of control of cell proliferation.70,71 Developmental pathways are critical
in HGPIN and PCa initiation and progression.72 The most fundamental epigenetic
changes occur as a result of chromatin remodelling, DNA methylation, histone
acetylation, alteration of transcriptional mechanisms and fusion translocations.72
These alterations can lead to gain of function as well as loss of function mutations.72
This way of thinking has given rise to the idea that cancer cells illicit an almost
Darwinian approach to survival.73 This is done by producing their own growth
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signals, reducing apoptosis, suppressing inhibition signals, angiogenesis and inducing
limitless replication potential and thus better competition for resources.73,74
Multiple studies have implicated genetic abnormalities in the progression of
PCa to castration resistant PCa (CRPC) and progression to the more aggressive
metastatic CRPC (mCRPC) and have elucidated possible avenues for more effective
or actionable treatments.75 The main genetic alterations which occur during the
progression of PCa to mCRPC were identified during a recent study investigating
the genetic landscape of PCa are shown in figure 1.3 below.75 Genetic alterations
were shown to result from single nucleotide variants, fusions, homozygous deletions
and amplifications.75 These alterations resulted in significant changes to multiple
pathways including AR signalling, phosphoinositide-3-kinase (PI3K/AKT), WNT,
DNA repair, cell cycle and gene modifier pathways.75
Figure 1.3: Integrative landscape analysis of somatic and germline aberrations
in metastatic CRPC obtained through DNA and RNA sequencing of clinically
obtained biopsies. Genes and their subsequent proteins can be further analysed to
determine their effect on PCa. Reproduced from Robinson, D. et al. Integrative
clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).75
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Chromosomal fusions were found to be a frequent feature of the various stages
of PCa with an average of 15 gene fusions per tumour being detected.75 These were
mostly made up of ETS transcription family (ETS) to ERG, ETS transcription
factor (ERG) fusions with less common fusions between ETS and Fli-1 proto-
oncogene, ETS transcription factor (FLI1), ETS variant 4 (ETV4) and ETS
variant 5 (ETV5).75 Furthermore, fusions between ETS and B-Raf proto-oncogene,
serine/threonine kinase (BRAF), phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha (PIK3CA), phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit beta (PIK3CB) and R-spondin 2 (RSPO2) were also identified
as potentially responsive to targeted therapy.75 The BRAF, PIK3CA/B and
RSPO2 act through regulation of the MAPK, PI3K/AKT and WNT pathways
respectively.76–78
Chromosomal fusions between transmembrane protease, serine 2 (TMPRSS2)
and ERG have also been shown to be highly prevalent.72 These involve ETS tran-
scription factors and TMPRSS2 and usually result in changes in the PI3K/AKT
pathway.72 AR signalling has been shown to induce TMPRSS2 and ERG prox-
imity.72 Proximity combined with recruitment of enzymatic cytidine deaminase
and the long interspersed element-1 (LINE-1) repeat encoded open reading frame 2
(ORF2) endonuclease that results in double stranded DNA breaks and subsequent
fusion through ligation by non-homologous end joining.72 TMPRSS2 is androgen-
inducible and is expressed in normal and PCa cells.79 Therefore the fusion of
TMPRSS2 with other genes allows them to become androgen inducible.79 The
final protein products of these fusions only include amino acids from the ERG gene
indicating the TMPRSS2 fusion region acts as the androgen inducible promoter.79
Thus the subsequent fusions allow upregulation of ERG, ETV1 and ETV4 in the
presence of androgens.79 ERG gene products regulate cell proliferation, differenti-
ation and apoptosis79 and TMPRSS2-ERG fusions therefore results in activation
of oncogenic pathways.72 TMPRSS2-ERG fusions also induce repressive epigenetic
programs upregulating Histone-lysine N-methyltransferase EZH2 (EZH2).72 ERG
and the AR work together and inhibit AR mediated differentiation and promote
EZH2 mediated dedifferentiation.72 High levels of ETS in fusion positive cases
also results in activation of RAS-responsive elements replacing the RAS-MAPK
pathway.72
Multiple individual pathways have been shown to affect PCa development.75
Many of these pathways and their constant interplay been shown to contribute to the
onset and development of PCa as indicated by figure 1.4.80 Alteration within the AR
signalling pathway were shown to be common.75 The main changes occur within the
AR itself, truncated or missense mutations in the forkhead box A1 (FOXA1) pioneer
transcription factor, disruption of the nuclear receptor corepressor 1 (NCOR1)
and nuclear receptor corepressor 2 (NCOR2) negative regulators, mutations of
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the putative transcription regulator speckle type BTB/POZ protein (SPOP) and
deletions of zinc finger And BTB domain containing 16 (ZBTB16).75 These result in
an upregulation of the MAPK pathway as well as hotspot mutations in residues on
the AR that confer agonism to AR agonists.75 The hepatocyte nuclear factor 3-alpha
(FOXA1) pioneer transcription factor is critical in the growth and differentiation of
prostate cells and has been shown to negatively inhibit the activity of the AR and
the PI3K/AKT pathway and thus has been implicated as a tumour suppressor.81
Zinc finger and BTB domain-containing protein 16 (ZBTB16) negatively regulates
transcription through binding to DNA and recruitment of co-repressors and has
been shown to suppress AR activity. Loss of function leads to tumour proliferation
as well as AR independence.82
The PI3K/AKT pathway was also shown to be significantly altered in many
cases, primarily as a result of biallelic loss of phosphatase and tensin homolog
(PTEN) as well as hotspot mutations, amplifications and activating fusions in
PIK3CA resulting in amplification and overexpression and the p.E17K activa-
tion mutation which leads to PI3K-independent activation of serine/threonine
kinase 1 (AKT1).75,83 There were also fusions of the PIK3CA and PIK3CB
resulting in overexpression increasing the activity of the PI3K/AKT pathway
which is responsible for cellular growth and proliferation.75,84 Phosphatidylinositol
3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
(PTEN) phosphorylates downstream targets such as phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) that results in the inactivation of the PI3K/AKT signalling
pathway and is a known tumour suppressor.72 While PTEN mutations are rare,
expression has been found to be greatly reduced resulting in the increased activity
of the PI3K/AKT pathway that has been shown to increase cellular resistance to
apoptosis.66
The WNT pathway is responsible for the direction of embryonic development
having specific effects on stem cell specification, proliferation, polarity, migration
and maintenance.80 Its interaction with the PI3K/AKT pathway, AR and proteins
such as PTEN and catenin beta 1 (CTNNB1) has been shown to contribute to
PCa tumourigenesis.80 Alterations in the WNT pathway were shown to result
from hotspot activations of CTNNB1, and recurrent alterations of APC WNT
signalling pathway regulator (APC). Furthermore, alterations in ring finger protein
43 (RNF43), and zinc and ring finger 3 (ZNRF3) were mutually exclusive to APC
mutations.75 Additionally RSPO2 fusions resulted in its overexpression.75
It is well know that PCa occurs as a result of changes in the cell cycle.75
The role of retinoblastoma transcriptional corepressor 1 (RB1) was implicated in
these changes as well amplifications of cyclin D1 (CCND1) and less commonly
cyclin dependent kinase inhibitor 2A/B (CDKN2A/B), cyclin dependent kinase
inhibitor 1B (CDKN1B) and cyclin dependent kinase 4 (CDK4).75 Retinoblastoma-
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associated protein (RB1) negatively regulates proliferation through mediation of
promoter regions of cyclin A2 (CCNA2) and minichromosome maintenance complex
component 7 (MCM7) as well as inactivation of E2F-mediated transcription.85
Changes in the DNA repair pathway have significant effects on PCa progression
with alterations of BRCA2, DNA repair associated (BRCA2).75 Breast cancer type
2 susceptibility protein (BRCA2) is a known tumour suppressor responsible for
mitigating DNA damage by efficient and precise repair of double-stranded DNA
breaks86 Biallelic loss of BRCA2 occurred as a result of somatic point mutations, loss
of heterozygosity and homozygous deletion.75 BRCA2 loss may also occur as result
of pathogenic germline mutations combined with somatic alterations resulting
in biallelic loss.75 There was also a large prevalence of biallelic loss of ATM
serine/threonine kinase (ATM).75 Alterations were also shown in BRCA1, DNA
repair associated (BRCA1), cyclin dependent kinase 12 (CDK12), Fanconi anaemia
complementation group A (FANCA), RAD51 paralog B (RAD51B), RAD51 paralog
C (RAD51C) as well as hypermutation events occurring as a result of structural
changes in mutL homolog 1 (MLH1) or mutS homolog 2 (MSH2).75
Figure 1.4: A Kyoto Encyclopaedia of Genes and Genomes (KEGG) representation
of the possible pathways implicated in the development and progression of PCa.
Protein upregulation and downregulation events can be analysed to determine their
individual effects on pathways. Reproduced from http://www.genome.jp/kegg-
bin/show pathway?hsa05215
Stellenbosch University  https://scholar.sun.ac.za
1.3. PROSTATE CANCER 13
1.3.4 Mortality
Cancer when detected early is usually treatable.3 The time taken to discover the
presence of cancer is directly linked to the final prognosis.87 Once the cancer has
metastasised it becomes far harder to treat and manage.87 The usual progression
of cancer is, pre-malignant, primary tumourigenesis, rapid genetic alteration,
metastasis and invasion.88 Once the cancer has fully spread treatment is still
possible but the likelihood of full recovery is unlikely and treatment usually focuses
on increasing quality of life or increasing life expectancy through the use of palliative
care.89 The progression from treatment failure to death is dependent on the spread
and grade of the cancer.90 This time period can run from weeks to years.91
Although cancer is the overall cause of mortality the actual causes of death can
be attributed to: infection, haemorrhages, thromboembolisms, organ invasion,
cachexia, respiratory failure and cardiovascular failure.92 It has been widely reported
that patients with higher qualities of life tend to live longer.93
1.3.5 Prostate cancer treatment
After diagnosis and classification a patient prognosis is determined outlining the
chances of survival and the overall seriousness of the cancer.90 The prognosis is
determined by a wide range of factors including the type and traits of the cancer.90
PCa treatment is highly controversial. Small benign tumours are primarily
treated with either surgical reduction (radical prostatectomy) or radiation therapy.94
Treatment is often unnecessary as tumours may have remained benign and treat-
ment has been shown to increase prostate cancer mortality.95 The next available
treatment option is Brachytherapy through the insertion of radioactive implants
directly into the prostate tissue.96 The final treatment option for more aggressive
cancers is androgen deprivation therapy (ADT) achieved through chemical or sur-
gical castration.97 Primary ADT utilises either a gonadotropin-releasing hormone
analog or gonadotropin-releasing hormone with or without an oral anti-androgen
resulting in combined androgen blockade therapy.98 This results in the reduction of
circulating androgens that has been shown to be highly effective resulting in large
amounts of apoptosis.99 However, in most cases the PCa eventually resurges as
the more aggressive CRPC.100 CRPC is treated using secondary ADT that utilises
anti-androgens and inhibitors of androgen production.101
1.3.6 Prostate cancer diagnosis
PCa screening and diagnosis is steadily becoming more widespread.102 Common
practice screening methods include the digital rectal examination (DRE),103 PSA
level testing103 and the prostate health index (PHI).104 The DRE and PSA level
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testing have been shown not to reduce the mortality of PCa.105 Positive DRE
and PSA results give no indication of the severity of PCa and require further
testing.106 The PHI is a mathematical model utilising PSA, free PSA and proPSA
that increases the sensitivity of PCa diagnosis.104 Further testing is highly invasive
and includes a transrectal ultrasound (TRUS) and transrectal ultrasound-guided
systemic biopsy107 that can result in complications.108 PSA has been shown to be
highly non-specific and thus necessitates the need for the development of a new
more effective diagnostic method.106
1.4 Biomarkers
1.4.1 Biomarker fact sheet
The term biomarker has multiple definitions.109 The broadest definition is an
objective indication of a medical state observed from outside the patient which can
be measured accurately and reproducibly.110 A more applicable definition is that
of the National Cancer Institute; “A biological molecule found in blood, other body
fluids, or tissues that is a sign of a normal or abnormal process, or of a condition
or disease. A biomarker may be used to see how well the body responds to a
treatment for a disease or condition. Also called molecular marker and signature
molecule.”109 The earliest example of a cancer biomarker was the discovery of light
chain of immunoglobulin in urine in 1848 that was indicative of myeloma.111 Since
then multiple biomarkers have been identified for multiple conditions including
PSA for prostate cancer which was identified in 1980.111
Biomarkers can come in a number of forms from the DNA to the metabolite
level.111 They can be characterised into three categories including, diagnostic,
prognostic and stratification and validated in terms of specificity and sensitivity.111
Specificity and sensitivity are often incorrectly used interchangeably.112 Specificity
refers to the portion of the population that are identified as true negatives while
sensitivity refers to those that are identified as true positives.111 Concurrently high
levels of specificity and sensitivity are very hard to attain and receiver operating
characteristic curves as demonstrated in figure 1.5 below are used to identify
potential biomarkers of high enough specificity and sensitivity.111 A diagnostic
marker must be highly specific and sensitive and must indicate a disease state.111
Prognostic markers are used after a disease state has been identified and is used
predict the progression of a disease, its possible reoccurrence as well as the possible
outcomes of treatment.111 Stratification or predictive biomarkers are used to predict
the effects of a treatment prior to treatment application that better help identify
patients who will respond to which treatment.111
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Figure 1.5: A receiver-operating curve representing the relationship between sens-
itivity and specificity used to evaluate the efficacy of a tumour marker at vari-
ous cut-off points. Receiver operating curves can be used to identify the true
positives, true negatives, false positives and false negatives. Reproduced from
http://www.nature.com/nrclinonc/journal/v5/n10/full/ncponc1187.html
The ideal characteristics of a good biomarker include the ability to increase
the survival rate or quality of life of a patient, ease of use, reliability and cost.111
Currently most biomarkers require further tests to successfully identify a disease
state.111 Specifically in cancer biomarkers a number of characteristics are ideal and
include: biomarkers produced by tumours and present in circulation; quantifiably
present at low quantities in healthy or benign tumour individuals and high in
diseased individuals; easily and cost effectively quantifiable; quantitatively relative
measurement to tumour burden; and high sensitivity and specificity.111
1.4.2 Prostate specific antigen
PSA was first identified in 1971 and its use as a clinical biomarker developed for
PCa in 1980.113 Initially it was deemed a highly promising biomarker, but has been
steadily discredited due to its low specificity and sensitivity.106 While elevated
levels of PSA were initially thought to be indicative of PCa it has been shown that
elevated levels of PSA are also present in patients presenting with other prostatic
conditions such as prostatitis and BPH.114 PSA may also become elevated due to
external prostate interactions such as the DRE or prostate biopsies.114 PSA is
therefore not indicative of PCa and has led to severe over-diagnosis often resulting
in unnecessary and often harmful further diagnostic and treatment procedures.106
Further unnecessary diagnosis may include core needle biopsies which themselves
may not be effective and potentially harmful.115
The lack of sensitivity and specificity of PSA has necessitated the development
for novel biomarkers and has yielded significant results.106 Several new biomarkers
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have been identified as potential diagnostic, prognostic and stratification biomarkers
including, disabled homolog 2-interacting protein (DAB2IP), Golgi membrane
protein 1 (GOLM1) proliferation marker protein Ki-67 (MKI67), TMPRSS2-ERG
fusion, prostate cancer associated 3 (PCA3 ), PDZ and LIM domain protein 4
(PDLIM4 ), caveolin-1 (CAV1), sarcosine, chromogranin A (CHGA), glutathione
s-transferase π (GSTP1 ) and alpha-methylacyl-coa racemase (AMACR).106
MKI67 is a promising prognostic biomarker for PCa.106 It has been shown to
predict the outcome of a radical prostatectomy in patients who are considered
low-stage or low grade PCa.106 It may allow more effective treatment and targeted
treatment of PCa.106
CAV1 is also potentially promising as it can differentiate between various
prostatic conditions based on the relative levels.106 Conditions such as BPH express
a large amount of CAV1 while early stage PCa expressed lower levels and metastatic
PCa showed no expression.106 This means that CAV1 may be useful in targeted
treatment and prognosis.106
GSTP1 is a promising diagnostic biomarker for PCa.106 The GSTP1 gene
has been shown to be unmethylated in normal prostate tissue and BPH tissue
and hypermethylated in PCa tissue.106 It is readily secreted into serum, urine
and seminal plasma meaning it can be easily and quantitatively analysed and is
indicative of early stage PCa and PIN.106 This is potentially the most promising
and useful biomarker for diagnosis and prognosis pre and post treatment.106
1.4.3 Biomarker discovery
Discovery of novel biomarkers falls into five distinct phases, preclinical explorat-
ory studies, assay development and validation, retrospective longitudinal clinical
repository studies, prospective screening studies and randomised control trials.111
Preclinical exploratory studies identify biomarkers by investigating differences
between normal and tumorigenic cells.111 Assay development and validation fo-
cuses on using a positive identification biomarker to develop a test for positive cases
only.111 Retrospective longitudinal clinical repository studies then check if negative
or early diagnosis can be achieved utilising the same biomarkers.111 Prospective
screening studies are the refinement of the assay to identify positive individuals as
well as the extent of the disease state.111 Finally randomised control trials are used
to identify the population wide effect of using the novel biomarker.111
Biomarkers can be discovered at every level of ’omics, namely genomics, tran-
scriptomics, proteomics, sectretomics, metabolomics and lipidomics.116 These
approaches are constantly becoming more powerful with modernisation and devel-
opment of new technology.111
Genomics and proteomics are the two most utilised methodologies. Genomics
utilises microarrays, northern blotting, standard gene expression techniques and
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serial analysis of gene expression while proteomics is further downstream and
utilises, mass spectrometry, 2D polyacrylamide gel electrophoresis, antibody arrays
and tissue microarrays.117
A very promising approach for proteomic biomarker discovery and improvement
is the use of tandem mass spectrometry.111 This field has slowly transitioned
from large solitary proteins to low molecular weight groups of proteins that can
increase sensitivity and specificity.111 Disease states and populations are highly
heterogeneous leading to a later focus on more broad identification of candidate
biomarkers.111 The proteomic level has a distinct advantage of upstream methods
such as genomics and transcriptomics as transcription and translation events do
not directly translate into a defined product and may undergo multiple changes
that may not directly indicate a disease state leading to the theory that proteins
hold more physiological characteristics than genes.118
A subsection of proteomics is secretomics that is the study of proteins secreted
into the surrounding environment such as serum or media.119 Secretome analysis is
becoming steadily more prominent for its success in identifying candidate biomarkers
that are inherently non-invasive to obtain.119 Secretomics samples are relatively easy
to obtain and changes in methodologies has refined the technique significantly.119
It is highly useful in cancer biomarker discovery as secreted tumorigenic proteins
are readily involved in tumour progression.119
There are two strategies in proteomics, top-down and bottom-up.120 Top-down
is the utilisation of intact proteins prior to ionisation and detection whereas bottom-
up proteomics utilises pre-digestion of proteins into peptides prior to ionisation.120
In a bottom up approach samples typically undergo isolation techniques prior to
digestion to increase the resolving power and add a level of information such as
subcellular location.121 Proteins are then digested either enzymatically or chemic-
ally.121 Trypsin is a commonly used enzymatic digestion agent and cleaves proteins
at lysine and arginine residues.122 Peptides then typically undergo fractionation by
liquid chromatography prior to MS analysis.122 Liquid chromatography allows for
the separation of peptides and can be coupled directly to the mass spectrometer,
thus reducing the risk of sample loss.122
1.4.4 Mass spectrometry
Mass spectrometry (MS) is the study of simple or complex samples by ionising
the components and sorting the resulting ions based on mass to charge (m/z )
ratio.123 The mass spectrometer was initially used to separate uranium ions during
the Manhattan project.124 A simple flow through of mass spectrometry involves:
the ionisation of a sample, separation of subsequent ions by their m/z ratio in
a magnetic or electric field and detection.120 In the case of proteins, ionisation
is achieved by electrospray (ESI) or matrix assisted laser desorption ionisation
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(MALDI).123 MALDI is more suited to intact mass analysis than ESI (top down
approach). This approach is, however, hampered by the complex fragmentation
patterns which are difficult to interpret using current algorithms.121 The majority
of proteomic studies, therefore employ ESI of proteins which are first enzymatically
digested into smaller peptide fragments (bottom up approach). ESI is then used
to induce positive or negative charges on ions through protonation/deprotonation
or cationisation.123 The resulting peptide ions are then accelerated using a highly
positively or negatively charged electric field and are then passed through various
types of mass analysers which filter the ions based on m/z ratio allowing only
selected ions to reach the detector at any given time123 A large variety of mass
spectrometers are available each with different configurations. This study made
use of an Oribitrap Fusion Tribrid mass spectrometer. These mass spectrometers
are highly efficient and provide a high throughput platform for conducting bottom
up proteomic studies.125 The standard Tribrid architecture combines an ionisation
source, quadrupole, dual pressure linear ion trap and an ultra-high-field Orbitrap
mass analysers.126 The individual components are discussed below.
Electrospray ionisation
ESI based mass spectrometers can be coupled to liquid chromatography based
separation systems. This allows for the separation of peptides prior to ionisation
thus reduces the complexity of peptides entering the mass spectrometer at any
given time.
ESI uses electrical energy to aid in the transfer of ions from liquid into the gas
phase allowing the identification of ions in solution.123 There are three parts to ESI,
the production and dispersal of a fine spray of droplets, solvent evaporation and
ion ejection from the highly charged droplets as depicted by figure 1.6.123 These
ions are ejected into a highly electrically charged tube with a polarity matched
to the ions.123 Furthermore, a nebulizing gas such as nitrogen is introduced to
the chamber shearing the ionic droplets which increases and enhances the flow
rate.123 As the ions are accelerated out of the tube and prior to detection by a mass
analyser a pressure and potential gradient is applied to aid in separation of the
ions.123 Furthermore, an increased temperature or the introduction of a nebulizing
gas may be applied to reduce the amount of solvent present. This decreases the
droplet radius and increases the surface charge density.123 Eventually the electric
field strength within the ions reaches its maximal limit that allows the ions to
overcome the surface tension of the droplet and be ejected into the gas phase.123,127
These ions then enter various types of mass analysers which filter the resulting ions
based on m/z ratio.123
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Quadrupole mass analyser Quadrupole analysers allow easy coupling to ESI
and are relatively small, robust, economical to operate.123 They utilise the m/z
ratio as their primary means of separating and identifying ions.123 Four parallel
rods are placed equidistant from one another.123 Equal DC voltages superimposed
with a radio frequency (RF) voltage are applied to each set of diagonal rods that
generates an electrical field that allows the ions to move forwards through the field
in an oscillatory motion.123 By setting the ratios of DC to RF voltage applied
to the rods the ions travel at defined amplitudes that are related to defined m/z
ratios.123 This allows the selection of ions at defined m/z ratios to reach the
detector or subsequent mass analysers and causes all other ions to collide with the
rods neutralising them and preventing them from being detected.123
Tandem quadrupole mass analyser Quadrupole mass analysers can be placed
in series resulting in a tandem quadrupole system, often denoted as MS2.123 Typical
tandem quadrupole systems contain three quadrupole analysers denoted as Q1,
Q2 and Q3.123 Q1 acts a pre-selection system selecting the ion of interest.123 The
ion of interest is then applied to Q2 which usually only utilises RF current and
contains an inert gas such as argon.123 The ions collide with the gas converting the
kinetic energy to internal energy, become activated and are further fragmented into
product ions using collision induced dissociation (CID).123,128 The product ions
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then enter Q3 where they are filtered by m/z ratio.
Ion trap mass analyser Ion trap mass analysers became available after quad-
rupole mass analysers and are more economical, smaller and allow tandem CID
monitoring.123 They consists of three hyperbolic electrodes: the entrance end cap
electrode, ring electrode and exit end cap electrode.123 The combination of these
allows the trapping and storing of ions between the entrance and exit cap allowing
highly specific analysis.123 Ions are usually pre-separated in a quadrupole mass
analyser before entering the ion trap through a small hole in the entrance end cap
electrode.123 A voltage is then applied to the electrodes to trap ions. Ions can
then be ejected at defined m/z ratios by altering the voltage of the electrodes.123
By applying a RF potential, an AC potential of constant frequency and variable
amplitude to the ring electrode a three dimensional quadrupolar field is generated in
the trapping area.123 This field traps the ions in an oscillating trajectory dependent
on the m/z rations of ions in the trapping cell.123 The ions are ejected from the
trapping cell by inducing instabilities through alteration of the electrode system
potentials.123 These ions are ejected in increasing m/z ratio in an axial direction
from the oscillating trajectory and then detected.123 Tandem MS can be used
whereby the precursor ion is selected in the trap and an inert gas is applied inducing
CID.123 The product ions are then ejected and detected.123 Product ions can be
retained in the trap and subjected to multiple rounds of CID that aids in the
differentiation of molecules that have similar structures.123 Ion traps analysers are
limited in their modes of acquisition and cannot utilise precursor or neutral loss
scans therefore reducing their quantification potential by ten times when compared
to tandem quadrupole systems.123
Quadrupole Time of Flight mass analyser Further advancements in mass
spectrometry led to the development of the quadrupole time of flight mass spectro-
meter (Q-TOF).129 The Q-TOF is similar to the triple quadrupole as it contains
two quadrupoles with the addition of time of flight (TOF) mass spectrometer as
depicted in figure 1.7.129 An additional pre-quadrupole may be added prior to the
two quadrupoles to aid in collisional dampening.129 Ions are generated through a
suitable ion source such as ESI or MALDI and travel through the initial RF only
pre-quadrupole. Ions collide with a high-pressure nebulizing gas which focuses the
ions by reducing energy spread and beam diameter and allows better transmission
through the subsequent quadrupoles and TOF analyser.129 Ions then travel through
the first quadrupole, which, during MS/MS is run in mass filter mode to select a
precursor ion of interest.129 The precursor ions of interest are transmitted to the
second quadrupole where they undergo fragmentation via CID.129 The interaction
of the ions with the collision gas further focuses the ions, which is critical for
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TOF analysis.129 Fragmentation may be avoided to obtain single mass spectra by
significantly reducing the collision energy but this is not recommended, as it does
not result in additional focussing.129 Ions are once again accelerated and ion optics
are used to focus the ions into the ion modulator portion of the TOF analyser.129
The modulator region is initially field free and allows the ions to proceed in their
original trajectory.129 A pulsed electric field is applied across the modulator gap
forcing the ions into an orthogonal trajectory and into an accelerating column where
they obtain the necessary energy for detection.129 The ions move into the field free
region for TOF mass separation.129 The ratio of energies is utilised to allow the
ions to proceed to the mass detector without external electric interference, which
may reduce the mass resolution.129 A single stage mirror is used to correct the
initial spatial spread of the ions.129 Any ions that have deviated from the original
vertical positions are focussed on a horizontal plane at the detector entrance.129
Ions collide with two microchannel plates, are detected and recorded by a time
to digital converter which counts the relative abundances of ions129 Counting can
be additionally improved through the use of a multiple anode detector to increase
dynamic range.129 The Q-TOF provides high mass accuracy, mass resolution and
sensitivity.129
Figure 1.7: A quadrupole Time of Flight mass spectrometer. Reproduced from
Igor V. Chernushevich,Alexander V. Loboda and Bruce A. Thomson.129
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Orbitrap mass analyser Mass spectrometry methodology is constantly evolving
requiring equipment capable of cost effective high performance data acquisition.130
Alexander Makarov built on the principles of the Kingdon ion trap, quadrupole
mass analyser and Fourier transform ion cyclotron resonance instrument to develop
the Orbitrap mass spectrometer.130 The Orbitrap is made up two electrodes: an
outer-barrel like electrode responsible for excitation and detection of ions and a
coaxial inner spindle-like electrode responsible for maintaining the ions orbital
motion.130,131 Active measurements are taken in the space between the electrodes.125
Orbitrap mass analysers measure multiple consecutive small packets of ions in a
short time frame and require coupled systems to allow continuous measurement of
ions.130 This was initially its major pitfall that was remedied through the use of a
coupled system.130 A coupled system usually involves and ionisation source such as
ESI, three tandem linear quadrupole mass analysers, a lens system and lastly the
Orbitrap itself.130 Initially ions generated from ESI and travel into the first and
second high-pressure quadrupoles where they are selected, guided and transported
to a third low-pressure storage quadrupole.125 As they enter the storage quadrupole
the ions come into contact with a nebulizing gas that slows downs the ions and
allows them to pool, accumulate and maintain their small spatial extent before they
ejected into the Orbitrap in distinct packets.124 Distinct packets improve the signal
to noise ratio and resolution.124 The architecture allows CID or higher-energy
CID at any stage of MS.125 Once enough ions have accumulated the exit lens of
the storage quadrupole is opened generating a strong electric field that forces and
accelerates the ions into the Orbitrap.124 As they pass through the exit ring a
small DC potential is applied that helps generate the axial motion utilised in the
Orbitrap.124 The ions enter the Orbitrap off centre to further increase the axial
motion and ensure the ions are travelling coherently.130,131 To further ensure the
ions are travelling coherently a small voltage is applied to one part of the outer
electrode that forces the ions into defined axial position and when the current
is removed the ions move in a coherent motion.130,131 At this stage the all the
ions have axial, radial and rotational motion.130,131 The ions possess identical
axial oscillations and amplitudes but ions with different m/z ratios will possess a
different frequency.124 The ions are trapped in the Orbitrap and cycle around and
oscillate back and forth along the inner electrode.124
Mass analysis can be achieved through two modes; Fourier transform and mass
selection instability (MSI) mode.130,131 Fourier transform mode utilises the outer
electrode to measure the coherent oscillations of the ions in the axial direction
through image current detection.130,131 The current image is then transformed
using Fourier calculations that generate mass spectra.130,131 Measurements taken
using Fourier transformations have extremely high resolution.130,131 MSI mode is
similar to traditional detection systems.130,131 Ions are ejected from the Orbitrap
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that collide with a dynode that generates secondary electrons, which are multiplied,
collected and detected.130,131 MSI can be achieved using either paramagnetic
resonance or resonance excitement.125 Paramagnetic resonance utilises a voltage
applied to the electrodes, which is varied sinusoidally with time.125 In resonance
excitation sinusoidally oscillations are applied to half of the outer electrode.125 The
advantage of MSI is that it allows storage of ejected ions for MS/Ms analysis and
can act as a filter by ejecting contaminating ions, which improves the dynamic
range.125
The Orbitrap reduces problems associated with normal quadrupole mass analys-
ers and ion traps such as low mass accuracy, limited linear range, high complexity,
and reduced charge capacity.125 This architecture results in extremely high resolu-
tion, mass accuracy and dynamic range.125
Mass spectrometry data acquisition
After mass analysis the ion data is converted to a graphical representation called
a mass spectrum indicating the m/z ratios and their relative abundances.123
Quantitative information is slightly harder to obtain.123 Utilising ESI-MS the ion
signal detected is proportional to ion concentration and independent to flow rate
and injection volume.123 Therefore it is important to incorporate reference sample
to account for loss accrued during sample preparation and variable detection during
mass analysis.123
Intact protein mass spectrometry (top down approach) has distinct advantages
and disadvantages. For instance information can be obtained on post-translational
modifications, polymorphisms and sequence variants with relative ease but intact
proteins are prone to developing multiple charge states, which undergo multiple
different fragmentation patterns, which prevent the accurate determination of
molecular masses.121,132 A more common approach is to digest the proteins to
peptide fragments prior to MS analysis (bottom up approach).133
The bottom up approach is an indirect method in terms of quantification
as it is based exclusively on protein abundance, which is measured by spectral
counting and the area under the peaks on ion chromatograms.122,134 Spectral
counting is the number of observed peptides normalised against the peptide in the
reference sample that was most abundant providing a relative measure of protein
quantity.122 This means this method is semiquantative and can’t account for sample
loss.135 Spectral counting is concentration specific and high abundance peptides
will be preferentially measured while, low abundance proteins are usually lost or
not significantly measured121 Although low abundance peptides may be lost the
reduction of proteins into peptides substantially increases the dynamic range.121
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Peptide and protein validation
Accurate identification of peptides and proteins is critical to the success of mass
spectrometry analysis.136 The large growth in mass spectrometry data sets has
necessitated the development of complex algorithms to remove computational
bottlenecks.128 Multiple algorithms and software packages are available to effi-
ciently process and convert raw binary based spectrum files such as .raw (Thermo
Scientific), .mzML (HUPO-PSI) and .pkl (Waters) into usable text based mass spec-
trometric data such as MGF (Matrix Science) or custom XML files (X!Tandem and
SEQUEST).136,137 There are two critical steps involved in downstream processing:
database searching and post processing.136
Peptide mass fingerprints (PMF) contained in the MS spectra and MS/MS
spectra containing fragment ion m/z ratios are generated and only contain pep-
tide information such as peptide masses and relative abundances this must be
converted back to protein identities by running the peptides against databases of
in silico digested proteins created from gene information as shown in figure 1.8
below.122,133,138 This increases the likelihood of identifying possible proteins but
may increase the likelihood of false positives.133 Specific parameters must be set
to increase the likelihood of correct protein identification.133 Parameters such as
setting the taxonomy of the samples, what enzyme was used, missed cleavages
from digestion and PTMs will reduce the likelihood of false positives.133 This
method also has the advantage that intrinsic information is retained, which can
aid in identifying isoforms, polymorphisms and PTM’s.133 Carefully setting search
parameters is critical for informative protein identification.133
Database search algorithms can be divided into three broad categories, fragment
search/peptide mass fingerprinting, de novo search, and spectral library search
algorithms.128 Search engines such as Mascot, SEQUEST and X!Tandem match
experimental spectra to theoretical proteins digested in silico.128 The theoretical
masses are then compared to the experimental masses to obtain peptide identities.128





In silico digest 







Figure 1.8: Schematic of the work flow of bottom up proteomics. Protein validation
is achieved by digesting proteins using a chemical or enzymatic agents resulting
in peptides, which are then, analysed using mass spectrometry. Theoretical mass
spectra are also generated in silico and the experimental mass spectra is then
compared theoretical mass spectra to obtain protein identities.
De novo searches such as NOVOR and PEAKS search through spectra previously
identified and match the spectra to the best possible database entry.128,139 This
method can be extremely time consuming if the search space is not reduced within
certain parameters.128
Spectral libraries such as MassBank use statistic parameters such as dot products
or cross-correlations to reduce spectra to statistically defined statistical scores that
are then searched and matched against a database.128 The principle of spectral
libraries dictates that protein fragmentation is statistically reproducible.128,140
Once the spectra has been matched and identified it must be processed to usable
information for downstream analysis.141 Software packages such as MaxQuant
and PeptideShaker have been developed that can process spectrum files and their
subsequent database data.142,143 The focus of these packages is to assign signific-
ances and probabilities to the identification of the protein identities.128 The use of
multiple algorithms and software packages increases the effectiveness of database
searching and post-processing.136 Packages such as Scaffold and ProteoWizard
have been developed that allow a more comprehensive understanding of mass
spectrometric data.144 Multiple new software packages are coming online each day
and are making analysis easier and more effective.145
Data filtering and quality control
Filtering of protein identification is critical in identifying significant matches.136
Examples of filtering approaches include original-score based filtering, group, Pep-
tideProphet, Percolator and local false discovery rate (LFDR). These are critical
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in correct peptide matching.136
The most common quality control strategy in place is the target decoy strategy
or original score based filtering whereby the spectrum data is shuffled into random
combinations and run across a database. The subsequent proteins identified then
act as a measure of how random the matching procedure is, resulting in the
false discovery rate (FDR).136 Further algorithms built on the FDR method were
developed to increase the statistical significance of identified of peptide identities and
reduce incorrect peptide spectrum matching (PSM).136 PeptideProphet utilises a
semi-supervised decoy method to estimate the probabilities of correct identities from
discriminant scores coupled with a linear discriminant analysis based classifier.136
Percolator uses a method whereby it identifies a subset of high confidence PSMs
using a support-vector-machine based classifier to select correct PSMs.136 LFDR
utilises a log likelihood ratio generated using a näıve Bayesian classifier.136
Experimental workflow
This study utilises a bottom up proteomic approach. An LC-ESI coupled to an
Orbitrap Tribrid Fusion MS as depicted in figure 1.9 results in high throughput
mass spectrometry approach.121 This system utilises proteins digested to peptide
fragments. These fragments were pre-separated by LC before being ionised using
ESI. Initial MS1 was performed prior to selection of precursor ions which were
then selected for fragmentation and fragmented using HCD. Fragment ions were
subsequently analysed using the Orbitrap mass analyser. Detected fragmented ions
were registered on binary .raw files which are and processed using the SequestHT
algorithm to obtain peptide sequences and relative abundances were calculated
and validated using X!Tandem The Orbitrap Tribrid Fusion architecture offers
multiple fragmentation modes to produce product ions from precursor ions including
collision-induced dissociation CID, higher-energy CID (HCD), electron-transfer
dissociation and electron transfer HCD at any stage of MS.126 Noise is actively
reduced using an active beam guide by preventing neutral ions and high velocity
ion clusters from entering the quadrupole mass filter.126 MS/MS precursor ion
selection can be achieved using the quadrupole mass filter with high ion transmission
from 50 to 3000 m/z .126 The Orbitrap mass analyser contains a nitrogen filled
C-trap and improves resolving power up to 500 000 full width at half maximum
(FWHM) and isotopic fidelity up to 240 000 FWHM at m/z 200.126 The ion-
routing multipole allows HCD as well as ion storage without fragmentation and
efficient and stable ion transfer between the ion routing multipole, the Orbitrap
and the linear ion trap mass analysers which is critical component of Orbitrap
mass analysers.126 The dual pressure linear ion trap contains a high-pressure cell
allowing MS precursor ion isolation from 0.2 amu to 600 amu and allows CID and
ETD.126 It also contains a low-pressure cell allowing improved scan speed, resolving
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power and mass accuracy.126 The dual dynode detector allows detection with a
high linear dynamic range that allows improved quantitation.126 This multiplexed
architecture allows, an effective mass range of 50 - 6000 m/z., resolution from 15000
to 500 000 FWHM, MSn scans from 1 to 10 and a dynamic range greater than
5000 in a single scan.126 The Orbitrap Tribrid Fusion MS in combination with a
bottom-up approach has the distinct advantage of allowing the identification of
protein identity and post-translational modifications of multiple proteins in the
same run. By analysing complex samples from tumour and non-tumour samples
a descriptive proteome can be identified that can reveal novel biomarkers for a
disease state.111
Figure 1.9: Schematic of an Orbitrap Fusion Tribrid mass spectrometer. The
Tribrid architecture combines a quadrupole, dual pressure linear ion trap and an
ultra-high-field Orbitrap mass analysers. Reproduced from Brooks/Cole, Cengage
Learning.
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1.5 Aims and objectives
The search for new non-invasive diagnostic tools for the identification of PCa
continues. This study aims to identify possible candidate biomarkers for PCa
through the elucidation of the proteome and secretome profiles of multiple prostate
cell lines. The specific objectives of this study are:
1. To optimise the growth conditions of a normal prostate cell line (PNT2C2),
a benign prostate hyperplasia cell line (BPH-1) and two prostate cancer cell
lines (PC-3 and LNCaP) in order to increase the amount of secreted proteins
produced while minimising cell death.
2. To optimise the detection rate of secreted proteins during mass spectrometry
by optimising and selecting the most suitable protein precipitation method.
3. To characterise and compare the proteome and secretome of the four prostate
cell lines with the aim of identifying changes unique to prostate cancer.
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Materials and methods
This study utilises an in vitro cell culture combined with mass spectrometry to
identify the intracellular proteins (proteome) compared to the secreted proteins
(secretome) with the goal of identifying possible candidate biomarkers to replace
PSA to aid in the diagnosis of PCa.
2.1 General materials and reagents
Roswell Park Memorial Institute 1640 growth medium (RPMI-1640), glucose
HybrimaxTM, Ham’s F12 Kaighn’s modified growth medium (HAMSF12K) con-
taining L-glutamine, acetone, methanol, chloroform, Coomassie brilliant blue G,
phosphotungstic acid, NaCl, EDTA, guanidine-HCl, octylgluco-mano-pyranoside
(OGP), methane methylthiosulphonate (MMTS), formic acid (FA) and trifluoro-
acetic acid (TFA) were all purchased from Sigma-Aldrich (St. Louis, USA). Sodium
pyruvate, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and foetal
bovine serum (FBS) were purchased from BioChrom (Cambridge, UK). Corning R©
75 cm2 and 175 cm2 CellBIND R© surface flasks and micro-centrifuge tubes were
purchased from Corning R© Life Sciences (NY, USA). T75 tissue culture flasks, 15
mL and 50 mL conical tubes were purchased from SPL Life Sciences (Gyeonggi-do,
Korea). Bovine serum albumin (BSA) and ammonium sulphate were purchased from
Roche Diagnostics (Mannheim, Germany) and Protea Chemicals (Western Cape,
South Africa), respectively. Trypan blue stain, 1% Penicillin-Streptomycin (Pen-
Strep), trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA), chemically defined
Chinese hamster ovary (CDCHO) medium and glutamine were purchased from
Thermo-Fisher Scientific (Massachusetts, USA). A lactate dehydrogenase (LDH)
standard was purchased from ScienCell Research Laboratories(California, USA).
Triscarboxyethyl phosphine (TCEP), triethylammonium bicarbonate (TEAB), and
UHPLC grade acetonitrile were purchased from Fluka (St. Louis, USA). Empore
29
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C18 extraction discs were purchased from 3M(St. Louis, USA). Sequencing grade
modified trypsin was obtained from Promega (Wisconsin USA).
2.2 Tissue culture
2.2.1 Cell line selection
Four cell lines representative of different states of the prostate were selected for the
comparative analysis of their proteome and secretomes. The lymph node carcinoma
of the prostate (LNCaP) representing androgen dependent malignant prostate
cancer146 and the human prostatic carcinoma (PC-3), representing androgen in-
dependent metastatic prostate cancer147 cell lines were selected to differentiate
between different stages of prostate cancer. The benign prostatic hyperplasia
epithelial (BPH-1) cell line was selected to represent a benign condition often
misdiagnosed as prostate cancer.148 Normal prostate epithelium cells immortalised
with SV40 (PNT2C2) were selected to represent healthy prostate cells.149 LNCaP,
PC-3 and PNT2C2 cell lines were purchased from the European Collection of
Authenticated Cell Cultures (ECACC), while the BPH-1 cell line was a generous
gift from S.W Hayward (Vanderbilt University, Nashville, Tennessee, USA).
2.2.2 Cell line maintenance
LNCaP cells were cultured in RPMI-1640 containing L-glutamine supplemented
with 2.5 g/L D-(+)-Glucose, 20 mM HEPES and 2 mM sodium pyruvate. BPH-
1 and PNT2C2 cells were cultured in RPMI-1640. PC-3 cells were cultured in
HAMSF12K containing L-glutamine. Each growth medium was also supplemented
with 10% FBS, 1.5 g/L sodium bicarbonate and 1% PenStrep. LNCaP cells were
cultured in CellBIND R© T75 tissue culture flasks, while all other cells were cultured
in T75 tissue culture flasks. All cell lines were cultured at 37◦C, 5% CO2 and
90% humidity. Cell counts were determined using the CountessTM automated
cell counter(Thermo-Scientific, California). All cell lines were routinely tested
for mycoplasma infection using the indirect Hoechst stain technique and only
mycoplasma negative cells were used for experiments.
2.2.3 Cell culture for proteome analysis
LNCaP, PC-3, BPH-1 and PNT2C2 cells were cultured for three passages to allow
successful establishment of log phase cells and increase overall cell number. Five
million cells of each cell line were subsequently seeded in 175cm2 CellBIND R©
surface flasks and grown to 80% confluency (±5 days). The growth medium was
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then aspirated and the cells collected using 4 mL trypsin-EDTA (0.05%) to detach
the cells from the flasks. The cells were transferred to conical tubes containing
40 mL of the appropriate growth medium. The cells were centrifuged at 626 x g
for 5 minutes and the growth medium aspirated and discarded. The cells were
then resuspended in 20 mL of phosphate buffered saline (PBS, pH 7.4), vortexed
and centrifuged at 626 x g for five minutes. The PBS was aspirated and discarded
and the cells were resuspended in 1 mL of PBS and transferred to a 2 mL micro-
centrifuge tube. The cells were then gently resuspended and centrifuged at 626 x g
for five minutes. The PBS wash step was repeated in order to ensure that all traces
of the growth medium was removed. The PBS was then aspirated and discarded
and the cells weighed and aliquots of 50 mg each were stored at -80◦C prior to
mass spectrometry analysis. Three biologically independent samples were collected
for each cell line.
2.2.4 Cell culture for secretome analysis
LNCaP, PC-3, BPH-1 and PNT2C2 cells were cultured for three passages as de-
scribed above. Each cell line was subsequently seeded into three 175cm2 CellBIND R©
surface flasks at three different seeding densities: LNCaP cells were seeded at 11,16.5
and 22 million cells per flask; PC-3 cells were seeded at 5, 8 and 11 million cells per
flask; BPH-1 cells were seeded at 2, 5 and 8 million cells per flask; and PNT2C2
cells were seeded at 4, 6 and 8 million cells per flask. The cells were then incubated
48 hours, with the exception of the LNCaP cells, which were incubated for 72 hours.
The regular growth medium was then aspirated and discarded. The cells were
subsequently washed three times with 30 mL PBS in order to remove any traces of
the original growth medium. CDCHO growth medium (30 mL) supplemented with
0.008 M glutamine was then added and the cells incubated for a further 48 hours.
A clean T175 flask containing only CDCHO was also incubated under the same
conditions to act as a negative control.
The CDCHO media was subsequently collected through gentle inversion of the
175cm2 flask. The collected growth medium was centrifuged at 626 x g for five
minutes to remove any excess cellular debris. The CDCHO media was subsequently
transferred to into 50 mL conical tubes. The cells remaining in the flasks were
collected using the aforementioned procedure, combined with the cellular debris and
washed three times with 10 mL of PBS. The samples were snap frozen and stored
at -80◦C until later use. Three biologically independent samples were collected for
each cell line.
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2.3 Protein determination of secretome samples
Secretome samples were defrosted overnight at 4◦C, vortexed and 1 mL aliquots
collected. Protein concentration was determined using the Coomassie assay (Brad-
ford).150 Standards (0 µg/mL - 100 µg/mL) were prepared using BSA and MilliQ
water (mH2O). Standards and samples (20 µL) were added in triplicate to a 96-well
flat-bottomed clear microtitre plate (Greiner Bio One International). Subsequently
100 µL of an in house Coomassie reagent was added. The plates were shaken on me-
dium for three seconds (Biotek Power wave 340 microplate spectrophotometer) and
incubated in the dark, at room temperature for 30 minutes. A modified approach
was used to increase the sensitivity of the assay.151 Absorbance was measured at
595 nm and 450 nm and a standard curve generated using the blank-corrected ratio
of absorbance at 595 nm over 450 nm. The blank-corrected ratio of each sample at
595 nm and 450 nm was calculated and compared against the standard curve to
calculate the protein concentration.









1 266 14 (of stock 2 mg/mL) 100
2 140 140 (of dilution 1) 50
3 140 140 (of dilution 2) 25
4 140 140 (of dilution 3) 12.5
5 140 140 (of dilution 4) 6.25
6 140 140 (of dilution 5) 2.125
7 140 140 (of dilution 6) 1.5625
8 140 0 0
9 70 0 0 (No dye = Blank)
2.4 Lactate Dehydrogenase determination
Cell death can be characterised by the quantification of plasma membrane damage.
Lactate dehydrogenase is a stable cytoplasmic enzyme that is released from the
cytosol of cells into the surrounding environment during cell death. Its concentration
is therefore a useful measurement of cell death and cytotoxicity. LDH levels can be
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measured using a colorimetric assay. During the assay reduced nicotinamide adenine
dinucleotide (NAD+) is reduced to oxidised nicotinamide adenine dinucleotide
(NADH + H+) by the LDH-catalysed conversion of lactate to pyruvate. In the
presence of the catalyst (diaphorase) NADH + H+ in turn reduces tetrazolium
salt (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride) (INT) to
form a formazan dye product. An increase in the amount of plasma membrane
damaged cells will cause an increase in the LDH enzyme which correlates to an
increase in the formazan dye product which can be detected at 495 nm using a
microplate spectrophotometer.152 LDH concentration was determined using the
lactate dehydrogenase assay from the cytotoxicity detection kit (Roche). Standards
(0 mU/mL - 200 mU/mL) were prepared using a LDH standard diluted with
CDCHO media from the negative control samples described above. Each standard
(10 µL) and sample (10 µL) were added in triplicate to a 96 well microtitre plate
followed by the addition of 100 µL of the reaction mixture to each well. Samples
were shaken on medium for three seconds and incubated in the dark for 30 minutes
at room temperature. Absorbance was subsequently measured at 495 nm and a
standard curve prepared. The relative levels of LDH in the samples were determined
by comparing the blank-corrected absorbance of the samples to the blank-corrected
standard curve. Samples with absorbance values, which were higher than the
highest value on the standard curve, were diluted using mH2O and the assay was
repeated.









1 560 140 (of stock 1 U/mL) 200
2 350 350 (of dilution 1) 100
3 350 350 (of dilution 2) 50
4 350 350 (of dilution 3) 25
5 350 350 (of dilution 4) 12.5
6 350 350 (of dilution 5) 6.25
7 350 350 (of dilution 6) 3.125
8 350 0 0 = Blank
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2.5 Protein precipitation of secretome samples
The proteins in the secretome samples were precipitated in order to increase the de-
tection of low abundance proteins during mass spectrometry analysis. Four methods
of protein precipitation were investigated using pooled secretome samples. These
included precipitation using acetone, ammonium sulphate, methanol/chloroform
and phosphotungstic acid (PTA) mediated acetone precipitation.
2.5.1 Acetone precipitation
Acetone was cooled overnight to -20◦C. The secretome samples (27 mL) were
transferred to 250 mL glass bottles and 108 mL of four volumes of acetone were
added to each sample. The samples were mixed and incubated for 24 hours at
-20◦C. The samples were subsequently centrifuged in 40 mL aliquots at 15000 xG
for 10 minutes and the supernatant was removed and discarded. The remaining
protein pellet was allowed to air-dry and was then resuspended in 1 mL mH2O.
The overnight reaction vessel was washed with 5 mL mH2O and transferred to the
pelleted sample to collect any remaining sample. The samples were then transferred
to 15 mL conical tubes and the original centrifuge tubes were washed with 1 mL
mH2O in order to collect any remaining sample. The samples were dried overnight
using a speedy-vac (LabConco Centrivap) to near dryness and then resuspended
in 2 mL mH2O. Protein concentration was determined using the aforementioned
procedure and samples snap frozen and stored at -80◦C until later use.
2.5.2 Ammonium sulphate precipitation
Samples (27 mL) were transferred to centrifuge 50 mL centrifuge tubes. Ammonium
sulphate (14.39 g) was added over a period of an hour while mixing in order to
achieve 80% saturation. The samples were then incubated for an hour at 4◦C to
allow for protein precipitation. The samples were subsequently centrifuged at 20000
xG for 30 minutes at 4◦C and the supernatant was removed and discarded. The
protein pellets were resuspended in 5 mL mH2O and transferred to 15 mL conical
tubes. The conical tube lids were pierced with a 0.5 cm radius hole punch. Dialysis
tubing (2500 Da) (Thermo-Scientific Snakeskin CA) was captured between the lid
and conical tube and checked for leaks through slow inversion. The dialysis vessels
were placed in 500 mL mH2O, 4
◦C and allowed to dialyse overnight at 4◦C under
constant light magnetic stirring. The mH2O was then changed and the samples
were dialysed for a further 4 hours after which the mH2O was again changed and the
samples dialysed for a further 4 hours. The samples were subsequently freeze-dried
to near dryness overnight using a speedy-vac, resuspended in 2 mL mH2O and
transferred to 2 mL micro-centrifuge tubes. Protein concentration was determined
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using the aforementioned procedure and samples snap frozen and stored at -80◦C
until later use.
2.5.3 Methanol chloroform precipitation
Samples were transferred to 500 mL centrifuge bottles. Four volumes of methanol
(108 mL) were added to the samples and samples were mixed vigorously. One
volume of chloroform (27 mL) was then added to each sample. Three volumes of
mH2O (81 mL) were subsequently added to the samples, which were then vortexed.
Samples were subsequently centrifuged at 14000 xG for 2 minutes. The top aqueous
layer was aspirated and discarded. Four volumes of methanol (108 mL) were added
to the samples and vortexed. The samples were centrifuged at 14000 xG for 3
minutes and the remaining methanol was aspirated and discarded. The remaining
sample was dissolved in 5 mL mH2O, transferred to 15 mL conical tubes, dried
overnight to near dryness and then resuspended in 2 mL mH2O and transferred to
2 mL micro-centrifuge tubes. Protein concentrations were determined using the
aforementioned procedure and samples snap frozen and stored at -80◦C until later
use.
2.5.4 Phosphotungstic acid (PTA) mediated acetone pre-
cipitation
The procedure was identical to acetone precipitation except that 1.2% phospho-
tungstic acid (w/v) was added to the acetone sample reaction vessel prior to
overnight incubation. Protein concentration was determined using the aforemen-
tioned procedure and samples snap frozen and stored at -80◦C until later use.
2.6 Mass spectrometric analysis
The 50mg whole cell and acetone-precipitated samples were sent to the Stellenbosch
Central Analytical Facility, Tygerberg, South Africa for mass spectrometric analysis.
2.6.1 Whole cell sample preparation
Cells were thawed in 100 µL extraction buffer and proteins extracted by grinding
the pellets with glass beads in extraction buffer containing; 100 mM NaCl, 2
mM EDTA, 6 M guanidine-HCl, 1% (v/v) OGP and 5 mM TCEP in 100 mM
TEAB (pH 7.8). After removal of the remaining pellet was washed with 100 µL
of 100 mM TEAB. The supernatants from were pooled and an overnight acetone
precipitation was performed with 5 volumes acetone. Thereafter, the samples
Stellenbosch University  https://scholar.sun.ac.za
2.6. MASS SPECTROMETRIC ANALYSIS 36
underwent centrifugation the pellets were air dried and dissolved in 100 µL 100 mM
TEAB containing 4 M guanidine-HCl and 1% OGP (v/v). Protein concentrations
were determined spectrophotometrically.
2.6.2 Sample digests
Samples were reduced by adding 1 µL of 50 mM TCEP in 90 µL 100 mM TEAB
(final concentration 5 mM TCEP) for 30 minutes at room temperature. Following
reduction cysteine residues were modified to methylthio using 1 µL 200 mM
MMTS in 10 µL 100mM TEAB (final concentration 10 mM) for 30 minutes. After
modification, the samples were diluted to 98 µL with 100 mM TEAB. Proteins
were digested by adding 5µL 1 µg/µL trypsin solution (1:20 ratio) and incubating
for 18 hours at 37◦C. The samples were dried down and resuspended in 100 µL 2%
(v/v) acetonitrile:water; 0.1% (v/v) FA.
2.6.3 Sample desalting
Residual digest reagents were removed using an in-house manufactured C18 stage
tip using C18 extraction discs The 20 µL sample was loaded onto the stage tip
after activating the C18 membrane with 30 µL methanol and equilibration with 30
µL 2% (v/v) acetonitrile:water; 0.1 FA. The bound sample was washed with 30 µL
2% (v/v) acetonitrile:water; 0.1% (v/v) FA before elution with 30 µL 50% (v/v)
acetonitrile:water 0.1% (v/v) FA. The eluate was evaporated to dryness. The dried
peptides were dissolved in 20 µL 2% (v/v) acetonitrile:water; 0.1% (v/v) FA for
liquid chromatography mass spectrometry (LC-MS) analysis.
2.6.4 Liquid chromatography
Liquid chromatography was performed on a Thermo Scientific Ultimate 3000 RSLC
equipped with a 0.5 cm x 300 µm ID C18 trap column and a 40 cm x 75 µm ID
in-house manufactured C18 column (Luna C18, 3.6 µM; Phenomenex) analytical
column. The solvent system employed was loading: 2% (v/v) acetonitrile:water;
0.1% (v/v) FA; Solvent A: 2% (v/v) acetonitrile:water; 0.1% (v/v) FA and Solvent
B: 100% (v/v) acetonitrile:water; 0.1% (v/v) FA. The samples were loaded onto the
trap column using loading solvent at a flow rate of 15 µL/minute from a temperature
controlled autosampler set at 7◦C. Loading was performed for 5 minutes before
the sample was eluted onto the analytical column. Flow rate was set to 500
nL/minute and the gradient generated as follows: 2.0%-10% B over 5 min; 5%-25%
B from 5-50 minutes using Chromeleon non-linear gradient 6, 25%-45% from 50-65
minutes, using Chromeleon non-linear gradient 6. Chromatography was performed
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at 50◦C and the outflow delivered to the mass spectrometer through a stainless
steel nano-bore emitter.
2.6.5 Mass spectrometry of whole cell samples
Mass spectrometry was performed using a Thermo Scientific Fusion mass spec-
trometer equipped with a Nanospray Flex ionisation source. The sample was
introduced through a stainless steel emitter. Data was collected in positive mode
with spray voltage set to 2 kV and ion transfer capillary set to 275◦C. Spectra were
internally calibrated using polysiloxane ions at m/z = 445.12003 and 371.10024.
Mass spectrometry scans were performed using the Orbitrap detector set at 120 000
resolution over the scan range 350-1650 with AGC target at 3x105 and maximum
injection time of 40 ms. Data was acquired in profile mode.
Tandem mass spectrometry acquisitions were performed using monoisotopic
precursor selection for ion with charges +2 - +6 with error tolerance set to ±10
ppm. Precursor ions were excluded from fragmentation once for a period of 30
seconds. Precursor ions were selected for fragmentation in higher-energy collisional
dissociation mode using the quadrupole mass analyser with HCD energy set to
32.5%. Fragment ions were detected in the Orbitrap mass analyser set to 15 000
resolution. The automatic gain control target was set to 1x104 and the maximum
injection time to 45 ms. Data was acquired in centroid mode.
2.6.6 Data analysis
The raw files generated by the mass spectrometer were imported into Proteome
Discoverer v1.4 (Thermo-Scientific, California) and processed using the SequestHT
(Thermo-Scientific, California) algorithm included in Proteome Discoverer. Settings
allowed for methylthio as fixed modification as well as NQ deamidation (NQ) and
oxidation (M). Precursor tolerance was set to 10 ppm and fragment ion tolerance to
0.02 Da. The Homo sapiens database from the Universal protein resource (UniProt)
was used for analysis. The results files were imported into Scaffold 1.4.4 (Proteome
Software, Oregon) and identified peptides validated using the X!Tandem search
algorithm included in Scaffold.
For comparative analysis between cell lines to ensure correct identification of
the proteome profile Stringent search engine constraints were set for the Sequest
database (Thermo-Scientific, California) to ensure correct identification of the
proteome profile. The fragment tolerance was set at 0.020 Da (monoisotopic),
precursor tolerance at 10.0 ppm (monoisotopic), fixed modifications at +46 on
C (methylthio), variable modification at +1 on NQ (deamidated), +16 on M
(oxidation) and +42 on n (acetyl) and maximum missed cleavages were set at 2.
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X! Tandem database identified proteins using the PeptideProphet algorithm
(The GM, thegpm.org) with Scaffold delta-mass correction with fragment tolerance
set at 0.020 Da (monoisotopic), precursor tolerance at 10.0 ppm (monoisotopic),
fixed modifications at +46 on C (methylthio), variable modification at -18 on n
(Glu->puro-Glu), -17 on n (Gln->pyro-Glu) and +1 on NQ (deamidated), +16 on
M (oxidation), +42 on n (acetyl) maximum missed cleavages at 2.
Peptide probabilities were assigned by the Scaffold Local FDR by Scaffold
(Proteome Software, Oregon). Constraints were set at 95% minimum for peptide
thresholds, 99% minimum for protein threshold and a minimum of 2 peptides, 0.0%
peptide FDR and 0.5% for protein FDR.
Proteins identifications were only accepted if the probability was above 99%
and contained at least 2 identified peptides. Proteins the contained similar peptides
and could not be differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony and proteins sharing significant peptide evidence
were grouped into clusters and later excluded prior to analysis.
Peptide and Protein validation were done using the Peptide and ProteinProphet
algorithms. GO annotations were retrieved from the NCBI database.
2.6.7 Ingenuity R© Pathway Analysis
The proteins identities for BPH-1, LNCaP and PC-3, their relative log2 fold change
ratios compared to PNT2C2 and their significance measured using the Benjamini-
Hochberg multiple test correction with a significance of p < 0.05 were analysed
using QIAGEN’s Ingenuity R© Pathway Analysis (IPA R© QIAGEN Redwood City,
www.qiagen.com/ingenuity)(IPA). A core analysis was run independently on each
cell line. Analysis parameters were set as follows: the reference set was the Ingenuity
Knowledge Base analysing direct and indirect relationships, interaction networks
were set to include endogenous chemicals with 35 molecules per network and 25
networks per analysis, all node types were measured, all data sources were included,
confidence was set at experimentally observed, species were set for all including:
human, mouse, rat and uncategorised, tissues and cell lines were ignored and
mutations were set to all. Focus was done on both upregulated and downregulated
molecules and experimental significance was set at p < 0.05. Canonical pathways,
upstream analysis, diseases and functions, regulator effects and networks were
reviewed and significant data was selected.
Comparative analyses were performed on the BPH-1, LNCaP and PC-3 cell
lines. Comparative canonical pathways, upstream analysis, diseases and functions,
regulator effects and networks were all reviewed. Biomarker analysis was performed
on proteins identified as unique to the LNCaP and/or PC-3 cell lines.
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Results
3.1 Cell culture optimisation
Previous studies have identified working seeding densities for the LNCaP and PC-3
cell lines and revealed that lower seeding densities generally result in lower levels
of cell death with comparatively higher levels of protein secretion.153 This study
builds on these findings by confirming the optimal seeding densities for the LNCaP
and PC-3 and investigating working seeding densities for the BPH-1 and PNT2C2
cell lines.
Optimal seeding densities were therefore confirmed prior to protein precipitation
and subsequent mass spectrometric analysis. The BPH-1, LNCaP, PC-3 and
PNT2C2 cell lines were each seeded at three different densities. After three rounds
of sub-culturing the normal media was removed, the cells were washed with PBS
and media was replaced with CDCHO media to minimise the presence proteins not
produced by the cells. After 48 hours (72 hours in the case of LNCaP cells) the
CDCHO media was collected and protein and LDH concentrations were determined
to ascertain which seeding density had the least amount of cell death with the
largest amount of protein secretion.
As might be expected the results indicate that protein concentration was highest
in the highest seeding densities with the exception of the difference between the
16.5x106 and 22x106 seeding density for LNCaP cell which was not significant
as shown in figure 3.1. LDH concentration was the lowest in the lowest seeding
densities for all cell lines with the exception of the LNCaP cells with showed no
significant difference between the seeding densities as shown in figure 3.2. The
ratio of LDH to protein concentration (figure 3.3) revealed that the optimal seeding
densities, as indicated by the lowest ratio of LDH to protein concentration, would
be the lowest seeding density for the BPH-1 and PC-3 cell lines. While the lowest
ratios tended to be obtained for the highest seeding densities for both the LNCaP
39
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and PNT2C2 cell lines these seeding densities were not significantly different from




































































































































Figure 3.1: Protein concentrations in CDCHO media conditioned using multiple
seeding densities of the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines. Results are
shown as the means ± SEM of three independent experiments each measured in
triplicate. Tukey’s post hoc test was applied and significance is indicated as ns (p
> 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001) and **** (p < 0.0001).
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Figure 3.2: LDH concentrations in CDCHO media conditioned using multiple
seeding densities of the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines. Results are
shown as the means ± SEM of three independent replicates measured in triplicate.
Tukey’s post hoc test was applied and significance is indicated as ns (p > 0.05), *
(p < 0.05), ** (p < 0.01), *** (p < 0.001) and **** (p < 0.0001).
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Figure 3.3: LDH/Protein concentrations ratios in CDCHO media conditioned using
multiple seeding densities of the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines.
Results are shown as the means ± SEM of three independent replicates measured
in triplicate. Tukey’s post hoc test was applied and significance is indicated as ns
(p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001) and **** (p < 0.0001).
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3.2 Protein precipitation
Protein precipitation methods are routinely used to increase the concentrations of
proteins, reduce the amount of solvent, dissociate proteins from carrier molecules
and to aid in the removal of contaminants.154,155
Four methods of precipitation were tested in this study in order to identify
the most appropriate method. These included: acetone precipitation; ammonium
sulphate precipitation; methanol/chloroform precipitation and PTA mediated
acetone precipitation. Samples from each seeding density were pooled for each
cell line and subsequently separated into five aliquots; four test samples and one
control. The resulting aliquots from each of the four cell lines were then used to
compare the four precipitation methods.
The results shown in table 3.1 and figure 3.4 indicate that acetone precipita-
tion method yielded the highest recovery while ammonium sulphate precipitation
resulted in the lowest measurable recovery. No protein was recovered from meth-
anol/chloroform precipitation as the methodology employed prevented the collection
of the protein interphase, while the protein concentration from the PTA mediated
acetone precipitation could not be accurately determined and this method was thus
excluded. Figure 3.4 lists the protein recovery as a percentage of protein recovered
compared to the control sample.
Table 3.1: Comparison of three methods used to precipitation proteins from
conditioned CDCHO medium. Samples were created by pooling three secretome
seeding densities from each cell line. The control was an aliquot of the pooled
samples that did not undergo precipitation. Results are shown as the means ±
SEM of four independent replicates measured in triplicate. Dunnetts’ post hoc test
was applied and significance is indicated as ns (p > 0.05), * (p < 0.05), ** (p <
0.01), *** (p <0.001) and **** (p < 0.0001).
Total recovery (µg/ml)
Control (µg/ml) Ammonium Sulphate Acetone Methanol + Chloroform
286 ± 66.4 90.9 ± 7.85 161 ± 10.7 0 ± 0
Significance ** ns ***
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Figure 3.4: The percentage recovery obtained using three methods to precipitate
proteins from conditioned CDCHO medium. Results were normalised against the
appropriate control sample by setting the control to 100%. Results are shown as
the means ± SEM of four independent experiments each measured in triplicate.
Dunnetts’ post hoc test was applied and significance is indicated as ns (p > 0.05),
* ( p < 0.05), ** ( p < 0.01), *** (p < 0.001) and **** (p < 0.0001).
3.3 Proteome analysis
3.3.1 Mass spectrometry guidelines
This study builds on countless previous works with the aim of fully categorising
tissue culture cell lines to aid in biomarker development as understand functional
differences between the cell lines.153,156 Furthermore, the analysis of cell line
secretomes is of great value for biomarker discovery as it is simpler than the analysis
of clinical samples which are complicated by the presence of high abundance proteins
which can mask the measurement of lower abundance proteins.157
While care was taken to minimise the amount of lysed cells during the collection
Stellenbosch University  https://scholar.sun.ac.za
3.3. PROTEOME ANALYSIS 45
of secretome samples in this study, cell lysis is unavoidable. The approach used in
this study was therefore to characterise the proteome as well as the secretome and
in so doing eliminate false positive biomarkers that may have contaminated the
secretome proteomic data. The analysis of the proteome also allows for differences
in functional pathways to be compared between the cell lines.
The BPH-1, LNCaP, PC-3 and PNT2C2 cell lines were all grown under optimal
conditions. After four rounds of sub-culturing the cells the cells were collected and
washed and aliquots prepared for mass spectrometric analysis. Three independent
biological replicates for each cell line were each injected in triplicate. The resulting
mass spectra were subsequently analyses using the SequestHT and X!Tandem search
engines and the integrated algorithms available in Scaffold and PeptideProphet
using stringent search parameters. All the data was subsequently imported into
Scaffold and protein identities were assigned using stringent parameters. Thresholds
were set at 95% minimum for peptide and 99% minimum for proteins. Proteins were
assigned using a minimum of 2 peptides and a FDR of 0.5%. The data acquired
in this study meets the standards The Minimum Information About a Proteomic
Experiment (MIAPE) guidelines158–160
The conversion rate from spectra to ID means were 18%, 20%, 21% and 19%
for BPH-1, LNCaP, PC-3 and PNT2C2 respectively.
3.3.2 Comparison of protein expression between cell lines
A total of 3576 proteins were identified in this study. Of these 1253 (35%) were
common to all cell lines, while 216 (6%), 431 (12%), 284 (8%) and 238 (7%) proteins
were unique to the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines, respectively. The
overlap of identified proteins is shown below in the Venn diagram (figure 3.5).
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Figure 3.5: Venn diagram showing the overlap of all proteins identified in the
proteome of the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines.
Scaffold was subsequently used to quantify the expression levels of proteins
(log2 fold change changes) in the BPH-1 (benign prostate hyperplasia), LNCaP
(androgen dependent prostate cancer) and PC-3 (androgen independent prostate
cancer) cell lines relative to the reference cell line PNT2C2 (normal prostate). A
T-Test with a Benjamini-Hochberg multiple test correction (n=36) was performed
by scaffold and p-values were determined for the fold change of each protein. This
data was subsequently analysed using the IPA software package.
3.3.3 IPA data analysis
Protein information was uploaded to IPA and 92% (BPH-1), 93% (LNCaP) and 93%
(PC-3) of proteins were correctly mapped to annotated identities from the GenPept
and UniProt/Swiss-Prot accession databases. All unidentified, non-annotated and
duplicated identities were discarded. Protein expression of the BPH-1, LNCaP and
PC-3 cell lines were compared against PNT2C2 protein expression and measured
using the log2 fold change ratio and a p-value cut off of 0.05 for all analyses. A
total of 51%, 52% and 53% of the proteins identified in the BPH-1, LNCaP and
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PC-3 cell lines were found to be expresses at a level which was significantly different
(p<0.05) to that of the PNT2C2 cell line.
Canonical pathway analysis
Canonical pathways represent idealised or generalised pathways that represent
common properties of a particular signalling module or pathway.161 Canonical
pathways give an indication of the changes of cellular functions and biological
pathways that can give insight into the pathways responsible for observed differences
in protein expression between cell lines. Tables 3.2, 3.3 and 3.4 list the top five
canonical pathways identified in the BPH-1, LNCaP and PC-3 cell lines, respectively
which were significantly different when compared to the PNT2C2 reference cell
line.
The results show that for the BPH-1 cell line the EIF2 signalling pathway, the
regulation of the eIF4 and p70S6K signalling, the protein ubiquitination pathway,
the mTOR pathway and the tRNA charging pathways were the most changed with
p-values ranging from 1.68x10-08 to 9.77x10-39and pathway coverage ranging from
19.1% to 33.3% (Table 3.2).
Table 3.2: Top five canonical pathways altered in the BPH-1 cell line relative to
the PNT2C2 cell line.
Name p-value Overlap (%) Overlap
EIF2 signalling 9.77x10-39 34.4 76/221






mTOR signalling 8.26x10-13 20.6 41/199
tRNA charging 1.68x10-08 35.9 14/39
The EIF2 signalling pathway, the mitochondrial dysfunction pathway, oxidative
phosphorylation proteins, the eIF4 and p70S6K signalling pathways and the remod-
elling of epithelial adherens junctions pathway were the the most changed in the
LNCaP cell line with p-values ranging from 2.66x10-11 to 4.93x10-28 and pathway
coverage ranging from 26.9% to 32.4%. (Table 3.3).
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Table 3.3: Top five canonical pathways altered in the LNCaP cell line relative to
the PNT2C2 cell line.
Name p-value Overlap (%) Overlap
EIF2 signalling 4.93x10-28 25.8 65/221
Mitochondrial dysfunction 1.72x10-18 25.1 46/171
Oxidative phosphorylation 2.68x10-15 27.5 33/109






The top five regulated pathways in the PC-3 cell line were the protein ubiquitin-
ation pathway, the EIF2 signalling pathway, the remodelling of epithelial adherens
junctions, tRNA charging and the epithelial adherens junction signalling pathways,
with p-values ranging from 7.66x10-11 to 1.18x10-16 and pathway coverage ranging
from 21.2% to 43.6%. (Table 3.4).
Table 3.4: Top five canonical pathways altered in the PC-3 cell line relative to the
PNT2C2 cell line.












The relative proportions of proteins that are upregulated, unchanged and
downregulated in the BPH-1, LNCaP and PC-3 cell lines when compared to
PNT2C2 are shown in figures 3.6, 3.7 and 3.8, respectively.
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This data shows that in the BPH-1 cell line 42%, 35%, 18%, 26% and 46% of
proteins matched to the EIF2 signalling pathway, the eIF4 and p70S6K signalling
pathways, the protein ubiquitination pathway, the mTOR signalling pathway and
the tRNA charging pathway, respectively were downregulated when compared to
PNT2C2, while 14%, 13%, 16%, 10% and 8% of the proteins were upregulated.
(Figure 3.6).
Figure 3.6: Top five canonical pathways altered in the BPH-1 cell line relative to
the PNT2C2 cell line. Green segments, grey segments and red segments indicate
the percentage of proteins that are downregulated, unchanged, or upregulated,
respectively when compared to the PNT2C2 cell line. The -log(p-value) indicates
the significance of the changes of BPH-1 when compared to PNT2C2 and was
calculated as a right tailed Fisher’s exact. Values at the end of the bars indicate
the total number of proteins in the respective pathways.
In the LNCaP cell line 16%, 2%, 4%, 15% and 41% of proteins matched to the
EIF2 signalling pathway, the mitochondrial dysfunction pathway, the oxidative
phosphorylation pathway, the protein ubiquitination pathway and the eIF4 and
p70S6K signalling pathways, respectively were downregulated when compared to
PNT2C2, while 33%, 36%, 39%, 28% and 13% of the proteins were upregulated.
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Figure 3.7: Top five canonical pathways altered in the LNCaP cell line relative to
the PNT2C2 cell line. Green segments, grey segments and red segments indicate
the percentage of proteins that are downregulated, unchanged, or upregulated,
respectively when compared to the PNT2C2 cell line. The -log(p-value) indicates
the significance of the changes of BPH-1 when compared to PNT2C2 and was
calculated as a right tailed Fisher’s exact test. Values at the end of the bars indicate
the total number of proteins in the respective pathways.
In the PC-3 cell line 16%, 16%, 26%, 10% and 16% of proteins matched to
the protein ubiquitination pathway, the EIF2 signalling pathway, the remodelling
of epithelial adherens junctions pathway, the tRNA charging pathway and the
epithelial adherens junction signalling pathways, respectively were downregulated
when compared to PNT2C2, while 22%, 29%, 32%, 46% and 18% of the proteins
were.
Stellenbosch University  https://scholar.sun.ac.za
3.3. PROTEOME ANALYSIS 51
Figure 3.8: Top five canonical pathways altered in the LNCaP cell line relative to
the PNT2C2 cell line. Green segments, grey segments and red segments indicate
the percentage of proteins that are downregulated, unchanged, or upregulated,
respectively when compared to the PNT2C2 cell line. The -log(p-value) indicates
the significance of the changes of BPH-1 when compared to PNT2C2 and was
calculated as a right tailed Fisher’s exact test. Values at the end of the bars indicate
the total number of proteins in the respective pathways.
Upstream regulator analysis
Upstream regulators are those proteins, molecules or upstream transcriptional
regulators that can explain the observed changes in the protein expression observed
in the BPH-1 LNCaP and PC-3 cell lines when compared to the PNT2C2 cell line.
Table 3.5, 3.6 and 3.7 list the top five upstream regulators identified by IPA for the
BPH-1, LNCaP and PC-3 cell lines, respectively. The results shows that the MYC,
5-Fluorouracil, MYCN, CD-437 and TP53 molecules are the most likely upstream
regulators for the BPH-1 and PC-3 cell lines, while MYC, 5-Flourouracil, MYCN,
CD-437 and ST1926 are the most likely upstream regulators in the LNCaP cell line.
MYC, MYCN and TP53 are proteins responsible for maintaining correct cell cycle
progression, apoptosis and cellular transformation and have known interactions
with multiple oncogenes such as RB1, CDKN2A/B, BRCA1, CDK12, MCM7
and CCNA2 that were in chapter 1 of this thesis.18,75 ST1926, CD-437 and 5-
Fluorouracil (FDA approved) are molecules that have shown promise as anti-cancer
and anti-tumour treatments.
P-values for the BPH-1 cell line ranged from 3.27x10-32 to 1.13x10-50. Inhibition
of MYC and MYCN could account for the changes seen in the BPH-1 cell line
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while predicted activations were unknown for 5-Fluorouracil, CD 437 and TP53
(Table 3.5).
















CD-437 CD-437 1.11x10-37 Unknown
TP53 Tumour protein p53 3.27x10-32 Unknown
P-values for the LNCaP cell line ranged from 1.38x10-35 to 1.10x10-48. Activation
of MYC and MYCN and inhibition of 5-Fluorouracil, CD 437 and ST1926 could
account for the changes seen in this cell line (Table 3.6).
















CD-437 CD-437 6.85x10-38 Activated
ST1926 ST1926 1.38x10-35 Inhibited
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P-values for the PC-3 cell line ranged from 2.04x10-28 to 1.58x10-55. Inhibition
of 5-Fluorouracil and CD-437 could account for the changes seen in the PC-3 cell
line while predicted activation were unknown for MYC, TP53 and MYCN (Table
3.7).











TP53 TP53 9.26x10-38 Unknown







The disease analysis function in IPA identifies the most likely disease related causes
of the measured changes in protein expression . Table 3.8, 3.9 and 3.10 list the
top five diseases which may cause the altered expression observed in the BPH-1,
LNCaP and PC-3 cell lines, respectively when compared t the PNT2C cell line..
The analysis shows that cancer, organismal injury and abnormalities, tumour
morphology, infectious diseases and reproductive system disease are the most likely
diseases that can explain the changes in all three of the cell lines, though the
ranking was slightly different between the cell lines.
P-values ranged from 5.31x10-05 to 4.28x10-48 for the BPH-1 cell line and the
number of proteins identified within the disease states ranged from 125 to 1146.
Interestingly cancer was identified as the top disease state in this cell line (Table
3.8).
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Cancer 5.31x10-05 - 4.28x10-48 1125
Organismal injury and abnormalities 5.31x10-05 - 4.28x10-48 1146
Tumour morphology 4.19x10-05 - 4.28x10-48 125
Infectious diseases 5.31x10-05 - 1.67x10-37 285
Reproductive system disease 5.31x10-05 - 1.19x10-23 585
In the LNCaP cell line the p-value ranged from 3.39x10-05 to 1.12x10-30 and
the number of proteins identified within the disease states ranged from 93 to 1170.
Infectious diseases ranked the highest in this cell line, followed by cancer (Table
3.9).




Infectious diseases 2.33x10-05 - 1.12x10-30 275
Cancer 3.54x10-05 - 3.06x10-30 1146
Organismal injury and abnormalities 3.54x10-05 - 3.06x10-30 1170
Tumour morphology 7.00x10-18 - 3.06x10-30 93
Reproductive system disease 3.39x10-05 - 1.51x10-19 580
Cancer was the top ranked disease state in the PC-3 cell line and the p-values
ranged from 2.39x10-04 to 1.90x10-29 and the number of proteins identified within
the disease states ranged from 91 to 1166. (Table 3.10).
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Cancer 2.93x10-06 - 1.90x10-29 1148
Organismal injury and abnormalities 2.93x10-06 - 1.90x10-29 1166
Tumour morphology 3.27x10-17 - 1.90x10-29 91
Infectious diseases 5.41x10-07 - 3.43x10-29 269
Reproductive system disease 2.39x10-04 - 1.80x10-22 588
Molecular and cellular function analysis
The molecular and cellular functions tool in IPA identifies those cellular functions
that can most likely explain the protein expression changes in the BPH-1, LNCaP
and PC-3 cell lines when compared to the PNT2C2 cell line. Table 3.11, 3.12 and
3.13 list top molecular and cellular functions for BPH-1, LNCaP and PC-3 cell lines
respectively identified using IPA. The results shows that cell death and survival,
cellular growth and proliferation, RNA post-transcriptional modification, protein
synthesis and cellular development are the most likely molecular and cellular events
that can explain the changes in the BPH-1, LNCaP and PC-3 cell lines when
compared to PNT2C2. Cell death and survival was the top ranked molecular and
cellular function identified in all three cell lines.
The p-values for the BPH-1 cell line ranged from 3.61x10-05 to 4.28x10-48 and
the number of proteins identified within the molecular and cellular functions ranged
from 102 to 544. (Table 3.11).
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Cell death and survival 4.96x10-05 - 4.28x10-48 544
Cellular growth and
proliferation
3.62x10-06 - 3.08x10-41 536
RNA post-transcriptional
modification
5.31x10-05 - 2.12x10-40 102
Protein synthesis 3.36x10-06 - 1.91x10-26 222
Cellular development 3.61x10-05 - 3.48x10-22 278
In the LNCaP cell line the p-values ranged from 1.55x10-05 to 1.11x10-37 and
the number of proteins identified within the molecular and cellular functions ranged
from 94 to 535. (Table 3.12).





Cell death and survival 3.45x10-05 - 1.11x10-37 535
RNA post-transcriptional
modification
2.34x10-06 - 4.44x10-33 94
Cellular growth and
proliferation
1.55x10-05 - 2.665x10-30 514
Protein synthesis 2.26x10-05 - 2.39x10-25 232
Cellular development 1.55x10-05 - 1.79x10-19 281
The p-values ranged from 2.28x10-06 to 3.49x10-52 in the PC-3 cell line and the
number of proteins identified within the molecular and cellular functions ranged
from 94 to 568. (Table 3.13)
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Cell death and survival 9.36x10-07 - 3.49x10-52 568
Cellular growth and
proliferation
2.28x10-06 - 3.38x10-48 555
RNA post-transcriptional
modification
5.03x10-09 - 5.51x10-35 94
Protein synthesis 5.52x10-07 - 1.36x10-29 241
Cellular development 2.28x10-06 - 4.27x10-21 273
GO term analysis
The analysis of GO term annotations for biological process, cellular location and
molecular function can provide further insights into the distribution and activity of
the proteins identified for the individual cell lines. This can aid the understanding
and interpretation of large data sets and provide information on local and integrated
functions throughout the cell lines.162,163 The use of pie and bar charts can
allow qualitative and semi-quantitative interpretation the biological significance of
proteomics data.158 Biological processes, cellular location and molecular function
information based on GO term annotations were retrieved from the NCBI database
for all proteins identified and the proportions of each GO term was calculated
in Scaffold and is listed in figure 3.9, 10 and 3.11, respectively below. It should
be noted that proteins may possess more than one GO term annotation and can
therefore be counted in multiple categories.
The relative proportions of proteins assigned to biological process GO terms are
shown in figure 3.9. Large proportions of identified proteins were assigned to cellular
process (18.48%) metabolic process (15.71%) and biological regulation (10.86%).
A smaller proportion (1-10%) of proteins were assigned to localisation, response to
stimulus, development process, multicellular organismal process, viral reproduction,
reproduction, reproductive process and multi-organism process. The percentage of
proteins assigned to locomotion, biological adhesion, rhythmic process, growth, cell
killing were under 1%. Of the biological processes 14.59% were unknown.
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18.48%  Cellular process
15.71%  Metabolic process
14.59%  Unknown
10.86%  Biological regulation
6.08%  Localization
5.96%  Response to stimulus
5.87%  Developmental process
5.75%  Multicellular organismal process
4.87%  Establishment of localization
2.44%  Immune system process
2.25%  Viral reproduction
1.90%  Reproduction
1.90%  Reproductive process
1.13%  Multi-organism process
0.85%  Locomotion
0.58%  Biological adhesion
0.40%  Rhythmic process
0.27%  Growth































































































































































Figure 3.9: The relative proportions of proteins that were assigned biological process
GO terms for the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines (A) and separately
for the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines respectively (B). GO term
annotations were retrieved from the NCBI database. Proteins may possess multiple
GO annotations.
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The relative proportions of proteins assigned to cellular component GO terms
are shown in figure 3.10. Large proportions of identified proteins were assigned to
intracellular organelle (15.95%), cytoplasm (14.32%), organelle part (12.55%) and
the nucleus (10.49%). A smaller proportion (10-1%) of proteins were assigned to
the membrane, extracellular region, plasma membrane, mitochondrion, organelle
membrane, cytoskeleton, endoplasmic reticulum, ribosome and Golgi apparatus.
The percentage of proteins assigned to the endosome was under 1%. 12.34% of the
proteins could not be assigned.
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15.95%  Intracellular organelle
14.32%  Cytoplasm




6.51%  Extracellular region
4.36%  Plasma membrane
3.68%  Mitochondrion
3.52%  Organelle membrane
2.91%  Cytoskeleton
1.36%  Endoplasmic reticulum
1.27%  Ribosome










































































































Figure 3.10: The relative proportions of proteins that were assigned cellular
components GO terms for the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines (A)
and separately for the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines respectively
(B). GO term annotations were retrieved from the NCBI database. Proteins may
possess multiple GO annotations.
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The relative proportions of proteins assigned to molecular function GO terms
are shown in figure 3.11. Large proportions of identified proteins were assigned to
molecular function (30.91%), binding (27.31%), unknown (18.99%) and catalytic
activity (12.52%). A smaller proportion (10 - 1%) of proteins were assigned to
structural molecule activity, enzyme regulator activity, transcription regulator
activity and transporter activity. The percentage of proteins assigned to molecular
transducer activity, translation regulator activity, electron carrier activity, motor
activity, auxiliary transport protein activity, chemoattractant activity, metallochap-
erone activity and protein tag were under 1%. A total of 18.99% of proteins could
not be assigned.
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30.91%  Molecular function
27.31%  Binding
18.99%  Unknown
12.52%  Catalytic activity
3.08%  Structural molecule activity
1.79%  Enzyme regulator activity
1.29%  Transcription regulator activity
1.27%  Transporter activity
0.94%  Molecular transducer activity
0.74%  Translation regulator activity
0.44%  Electron carrier activity
0.23%  Motor activity
0.21%  Antioxidant activity
0.17%  Auxiliary transport protein activity
0.04%  Chemoattractant activity
0.04%  Metallochaperone activity






































































































































































Figure 3.11: The relative proportions of proteins that were molecular function GO
terms for the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines (A) and separately
for the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines respectively (B). GO term
annotations were retrieved from the NCBI database. Proteins may possess multiple
GO annotations.
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Candidate biomarker selection
Membrane bound and extracellular proteins have previously been used as the best
possible candidate biomarkers as they are easily secreted into serum and can be
analysed non invasively.164 Scaffold was utilised to retrieve GO terms from the
NCBI database and identify membrane and extracellular proteins from the BPH-1,
LNCaP, PC-3 and PNT2C2 whole cell proteome. A total of 1176 proteins containing
membrane bound and/or extracellular GO term annotations were identified. Of
these 544 (46%) were common to all cell lines, 56 (5%), 93 (8%), 59 (5%) and 58
(5%) proteins were unique to BPH-1, LNCaP, PC-3 and PNT2C2, respectively.
The overlap of identified proteins is shown below in the Venn diagram (figure 3.12).
Figure 3.12: Venn diagram showing the overlap of membrane bound and/or
extracellular proteins identified in the proteome of the BPH-1, LNCaP, PC-3
and PNT2C2 cell lines.
The analysis of this data is useful for narrowing down proteins which may be
useful as candidate biomarkers unique to prostate cancer. The membrane and
extracellular proteins which were unique to the prostate cancer cell lines, LNCaP
and PC-3, or which occurred in both LNCaP and PC-3 cells, but not BPH-1 or
PNT2C2 cells were therefore identified and are listed in supplementary tables 5.1 -
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5.3. These proteins represent potential candidates biomarkers for PCa, which can
be investigated further.
Several candidate biomarkers were identified that were unique to the LNCaP
and PC-3 cell lines. The biomarker filter function was used to identify interesting
proteins and extracellular and plasma membrane proteins that were unique to the
LNCaP and PC-3 cell lines were selected. Table 3.14 and 3.15 lists a number of
proteins which may act as candidate biomarkers identified in the whole cell samples.
Table 3.14: Candidate biomarkers from the proteome for the LNCaP cell line
identified using IPA.





Q12955 ANK3 HUMAN Ankyrin-3 (ANK-3) (Ankyrin-G) ANK3 9.20x10-03
C9JJX6 C9JJX6 HUMAN




Glutamate carboxypeptidase 2 (EC 3.4.17.21)




carboxypeptidase II) (GCPII) (Membrane
glutamate carboxypeptidase) (mGCP)
(N-acetylated-alpha-linked acidic dipeptidase
I) (NAALADase I) (Prostate-specific











Prostate-specific antigen (PSA) (EC
3.4.21.77) (Gamma-seminoprotein) (Seminin)














Na(+)/H(+) exchange regulatory cofactor
NHE-RF2 (NHERF-2) (NHE3 kinase A
regulatory protein E3KARP)
(SRY-interacting protein 1) (SIP-1)
(Sodium-hydrogen exchanger regulatory
factor 2) (Solute carrier family 9 isoform A3
regulatory factor 2) (Tyrosine kinase
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Table 3.15: Candidate biomarkers from the proteome for the PC-3 cell line identified
using IPA.






CD97 antigen (Leukocyte antigen CD97) (CD
antigen CD97) [Cleaved into: CD97 antigen
subunit alpha; CD97 antigen subunit beta]
CD97 3.40x10-02
Q9Y2D5 AKAP2 HUMAN
A-kinase anchor protein 2 (AKAP-2)







Annexin A6 (67 kDa calelectrin) (Annexin
VI) (Annexin-6) (Calphobindin-II) (CPB-II)





F8VUA2 F8VUA2 HUMAN Charged multivesicular body protein 1a CHMP1A 1.90x10-03
Q9Y696 CLIC4 HUMAN
Chloride intracellular channel protein 4
(Intracellular chloride ion channel protein
p64H1)
CLIC4 1.00x10-04




adenylyltransferase) (EC 2.7.7.75) (Domain
G); Molybdopterin molybdenumtransferase







Integrin alpha-6 (CD49 antigen-like family
member F) (VLA-6) (CD antigen CD49f)
[Cleaved into: Integrin alpha-6 heavy chain;
Integrin alpha-6 light chain; Processed
integrin alpha-6 (Alpha6p)]
ITGA6 1.00x10-04














Partitioning defective 3 homolog (PAR-3)
(PARD-3) (Atypical PKC
isotype-specific-interacting protein) (ASIP)





















synthase-associated protein 1 (PRPP




Q5QPE2 Q5QPE2 HUMAN Protein transport protein Sec23B (Fragment) SEC23B 3.80x10-03
H3BN50 H3BN50 HUMAN




Wiskott-Aldrich syndrome protein family
member 2 (WASP family protein member 2)
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3.4 Secretome analysis
Following the optimisation of seeding densities for the production of secretome
samples (Section 3.1) and the optimisation of the protein precipitation method
(Section 3.2) three independent biological replicates were collected and prepared
for analysis by MS. Unfortunately, the due to technical difficulties experienced
resulting from construction in the building in which the MS is housed the MS had
to be taken off line and will only be brought online following the completion of the
renovations in 2017. As a result these samples could not be analysed in time for
the completion of this MSc thesis.
Preliminary data secretome data used to test the proof of concept was, however,
acquired at an earlier date. It should, however, be noted that while this data was
acquired using the same criteria as the samples described above, they only included
a single biological replicate, and the proteins were precipitated using ammonium
sulphate prior to analysis.
Scaffold was utilised to obtain protein identities for the BPH-1, LNCaP, PC-3
and PNT2C2 secretome samples as previously described for the proteome (section
3.3). A total of 1106 proteins were identified. Of these 310 (28%) were common to
all cell lines, 34 (3%), 266 (24%), 103 (9%) and 46 (4%) proteins were independent
to BPH-1, LNCaP, PC-3 and PNT2C2, respectively as shown in the Venn diagram
below (figure 3.13).
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Figure 3.13: Venn diagram showing the overlap of all proteins identified in the
secretome of the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines.
As previously stated membrane bound and extracellular proteins have previously
been used as the best possible candidate biomarkers as they are easily secreted
into serum and can be analysed non invasively.164 Scaffold was utilised to retrieve
GO terms from the NCBI database and identify membrane and extracellular
proteins from the BPH-1, LNCaP, PC-3 and PNT2C2 secretome. A total of 393
proteins containing membrane bound and/or extracellular GO term annotations
were identified using the NCBI database, of these 147 (37%) were common to all
cell lines, 5 (1%), 67 (17%), 31 (8%) and 10 (3%) proteins were unique to BPH-1,
LNCaP, PC-3 and PNT2C2, respectively. The overlap of identified proteins is
shown below in the Venn diagram (figure 3.14).
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Figure 3.14: Venn diagram showing the overlap of membrane bound and/or
extracellular proteins identified in the secretome of the BPH-1, LNCaP, PC-3
and PNT2C2 cell lines.
The analysis of this data is useful for narrowing down proteins which may be
useful as candidate biomarkers unique to prostate cancer. The membrane and
extracellular proteins with were unique to the prostate cancer cell lines, LNCaP
and PC-3, or which occurred in both LNCaP and PC-3 cells, but not BPH-1 or
PNT2C2 cells were therefore identified and are listed in supplementary tables 5.4
- 5.6. Proteins that have previously been reported as potential biomarkers were
identified are listed in table 3.16 and 3.17. These proteins therefore represent
candidates which can be investigated further as biomarkers for PCa.
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Table 3.16: Candidate biomarkers for prostate cancer identified from the secretome
using IPA.





Q12955 ANK3 HUMAN Ankyrin-3 (ANK-3) (Ankyrin-G) ANK3 7.20x10-03
P54105 ICLN HUMAN
Methylosome subunit pICln (Chloride
channel, nucleotide sensitive 1A) (Chloride
conductance regulatory protein ICln) (I(Cln))







Clathrin heavy chain 1 (Clathrin heavy chain








(Interferon-induced 15 kDa protein)
(Interferon-induced 17 kDa protein) (IP17)










cDNA FLJ53769, highly similar to Homo
sapiens nebulette (NEBL), transcript variant
2, mRNA
N/A 2.30x10-02





Spectrin alpha chain, non-erythrocytic 1
(Alpha-II spectrin) (Fodrin alpha chain)






Spectrin beta chain, non-erythrocytic 1
(Beta-II spectrin) (Fodrin beta chain)








PCa is the second most common cause of cancer internationally and has an estimated
mortality rate of 6.6%.23 PSA has been the industry standard biomarker and test
for PCa since its discovery in 1971 and approval by the FDA in 1986.113,165,166
PSA was initially thought to be an effective test for PCa that could be obtained
non-invasively through a blood test.106 In 1994 the FDA approved the simultaneous
use of the DRE in asymptomatic men.167 Subsequently, PSA was found to be
increased in patients with more benign conditions such as BPH and prostatitis.114
The large incidences of false positives, misdiagnosis and the lack of tangible benefits
in terms of reducing mortality of the PSA/DRE further decreased the confidence
in its diagnostic potential.105,106,114 PSA has since been widely criticised and
discredited with the initial discoverer of the PSA test Dr Richard Ablin stating that
it is not a reliable indicator of PCa.168 Subsequently the U.S. Preventive Services
Task Force in agreement with the FDA recommended that PSA not be used as
screening methods for PCa.169
As a result constant research has been undertaken to develop novel non-invasive
biomarkers that could not only identify PCa but also indicate the severity and
possible progression of the disease and give an indication of the most beneficial
treatments.75 The introduction of the PHI which utilises PSA, proPSA and
fPSA and mathematical modelling has significantly increased the efficacy of PCa
diagnosis.104 Several new promising biomarkers are currently in development
including PCA3, TMPRSS2:ERG, and the combinational use of several biomarkers
at once such as ProMARK and ConfirmMDx.170
Prostate cancer is a complex and variable disease and the utilisation of clinical
samples does not usually provide unbiased reliable biomarkers without an extremely
large sample size.171 This study contributed to the search for novel biomarkers
70
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by investigating differences in cancerous, benign and normal prostate tissue cell
lines. It was hypothesised that there may be distinct protein profiles in terms of
protein expression levels and unique proteins that could act as potential diagnostic
tools for PCa. The primary goal of this study was therefore to identify potential
biomarker candidates and to confirm the presence of candidate biomarkers identified
by previous studies by characterising the proteome and secretome of the BPH-1,
LNCaP, PC-3 and PNT2C2 cell lines. The culturing conditions of the four lines
were therefore optimised for mass spectrometric analysis and an in depth analysis
of the proteome and secretome profiles were performed.
4.2 Cell culture optimisation
Accurate determination of biomarkers in secretome samples dictates that the
presences of intracellular contaminating proteins released during cell death is
minimised.172 This was achieved by optimising the initial seeding densities (11400 -
126 000 cells per cm2) of the cell lines to increase protein secretion while minimising
cell death. Furthermore, a chemically defined serum free media (CDCHO) was
used to reduce the presence of interfering proteins.
By measuring the ratio of LDH to protein concentration the lowest seeding
densities for BPH-1 and PC-3 cell lines and the highest seeding densities for
LNCaP and PNT2C2 cell lines were shown to be the most optimal for mass
spectrometric analysis as seen in figure 3.3. Previous work by Makridakis et al.,
Sardana et al., Kulasingam et al. and Gunawardana et al. has shown that lower the
seeding densities tend to be more optimal for mass spectrometric analysis.153,173–175
However, while Sardana et al. observed this trend in PC-3 cells, the same trend
was not observed in LNCaP cells therefore suggesting that the optimal seeding
density is not necessarily the lowest in all cases but may be linked to the cell line
in question.153
While the higher seeding densities tended to result in the lowest LDH/protein
ratio for the LNCaP and PNT2C2 cell lines in this study, it should be noted that
the determined ratios were not significantly different from those obtained at other
lower seeding densities (Figure 3.3). It was therefore also important to consider
the absolute LDH concentration, as this is an indication of cell lysis, which could
potentially complicate the analysis of the secretome. The lowest seeding densities
were therefore used for secretome analysis in all four cell lines as these tended to
contain the lowest LDH levels and adequate protein concentrations. Although it
was tempting to reduce the seeding density even lower than the range tested in
this study Sardana et al. and Peh et al. have previously shown that this had no
significant benefit on cell culture optimisation.153,176 Conversely, Peh et al. showed
that unfavourable cell morphology and dispersion was significantly higher at very
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low seeding densities (2500 and 5000 cells per cm2). Furthermore, Sardana et al.
found that medium seeding densities in the LNCaP (85 700 cells per cm2) resulted
in higher LDH concentrations compared to higher seeding densities (126 000 cells
per cm2). Sardana et al also showed that low seeding densities (10 900 - 42 900
cells per cm2) in the PC-3 cell line reach a limit whereby decreasing the seeding
density does not result in decreased cell death.153
While cell culture conditions can be optimised to minimise cell lysis, this cannot
be eliminated completely. This study therefore employed an additional approach,
whereby the proteome of each cell line was also characterised. This proteome
profile containing possible contaminant intracellular proteins was subsequently
used as a reference when investigating the secretome in order to improve the
likelihood of identifying candidate biomarkers which were true secreted proteins.
It should, however, be noted that while this approach can aid in interpreting the
ambiguity brought about intracellular leakage it does not eliminate the effect of
the intracellular proteins on the dynamic range measured by the MS and thus
minimising these proteins therefore remains important.
In summary, the results obtained in this study confirm the trend observed
previously that low but not extremely low seeding densities tend to produce a
more optimal LDH to protein concentration ratio. The approach used in this
study confirmed the optimal seeding densities for the LNCaP and PC-3 cell lines
previously identified by Sardana et al. and led to the successful identification of
optimal seeding densities for the BPH-1 and PNT2C2 cell lines.
4.3 Protein precipitation
Mass spectrometry is inherently a concentration dependent technique.121 A bottom
up approach is very sensitive to individual peptide concentration and this has an
effect on protein identification and subsequent quantification.121,123 Therefore, it is
important to increase the concentration of proteins prior to mass spectrometry to
significantly increase not only the number of the proteins identified but also the
significance of the identities.
Even though mass spectrometry based proteomics is a very sensitive technique,
the identification and quantification of proteins from secretome samples requires a
step to concentrate the proteins prior to analysis.177 Secretome samples obtained
from the collection of CDCHO media from tissue culture samples were therefore
subjected to ammonium sulphate, acetone, methanol/chloroform and PTA-mediated
acetone precipitation in order to determine which precipitation method would yield
the best recovery.
Ammonium sulphate precipitation, also known as salting out, reduces the hy-
dration layer, reducing surface charges increasing hydrophobic interactions between
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proteins and initiates protein-protein interactions which forces mostly hydrophobic
proteins out of solution.178 Unfortunately, the additional salt which needs to be
removed, usually using dialysis, can result in unwanted protein losses.179 Acetone
precipitation exploits the difference of dielectric constants in water and proteins.179
The high dielectric constant of water allows it to have stable interactions with
proteins.179 These interactions can be reduced through the addition of an organic
solvent with a low dielectric constant such as acetone.179 Acetone reduces the
dispersion of proteins and lowers the effective dielectric constant of water allowing
aggregation of proteins.179 As this method reduces the hydrophobic effect it results
in proteins denaturing, which can make them difficult to re-solubilise.179,180 Non-
etheless, acetone is an effective means of sample preparation allowing removal of
contaminants while simultaneously concentrating proteins.179 Methanol chloroform
utilises a phase separation principle to trap and concentrate proteins between an or-
ganic and inorganic layer of solvents.179 The addition of methanol causes proteins to
form a hydrophobic and hydrophilic layer at the interphase.179 Subsequent removal
of the aqueous layer and the addition of chloroform allows the collection of the
proteins.179 It acts an effective means of collecting proteins free of contaminants.179
Unfortunately, not all proteins are precipitated as this method favours hydrophobic
proteins.179 PTA acetone precipitation works on a combinational approach using
the acetone to precipitate hydrophobic proteins and the PTA facilitating further
precipitation of polar proteins through negative ion precipitation.181 The addition
of PTA to an acidic media solution results in positively charged proteins binding
to PTA resulting in the precipitation of the proteins in their salt form.182 This in
an effective means of recovering a high concentration of diverse proteins.181
The results obtained in this study (Table 3.1 and Figure 3.4) show that acetone
precipitation resulted in the highest recovery (56%). The recovery obtained using
ammonium sulphate precipitation was substantially lower (35%) and no protein was
recovered when using the methanol chloroform method (0%). It should be noted
that an interphase of possible proteins was observed during methanol chloroform
precipitation but, could not be recovered. Furthermore, as this method favours
the purification of hydrophobic proteins, it is likely that more polar water soluble
secreted proteins would be easily lost during methanol chloroform precipitation.183
The protein concentration from the PTA-mediated acetone precipitation could
not be accurately determined and this method was thus excluded. This is likely
due to the use of the Bradford assay which was chosen as it is more robust in
determining protein concentrations in the presence of interfering agents,184 but
which can affected by the relative pH of the samples.151 The addition of PTA
may therefore have accounted for inconsistent results when using the Bradford
assay. The presence of large precipitates that were difficult to re-solubilise post-
precipitation may also have interfered with spectrophotometric measurements,
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thereby compromising the reliability of the assay.
The observation that the acetone precipitation method yielded the largest
recoveries is in agreement with previous investigations by Yuan et al., Duan et al.
and Sickmann et al. which showed that acetone precipitation was a superior method
when compared to other sample preparation methods such as ultrafiltration, dialysis,
TCA/acetone precipitation, ethanol precipitation, bio-spin columns and strong
cation exchange chromatography.185–187 Moreover, the use of acetone precipitation
allows for the increased recovery of smaller proteins, which get trapped in the
hydrophobic space between larger proteins.179 Acetone precipitation therefore
allows for superior recovery due to decreased handling and expedited processing
as no sample clean-up is necessary. While the recovery achieved in this study was
lower than that reported by Yuan et al. (94%) it was substantially higher than
that achieved by Sickmann et al. (40-50%) and Sardana et al. (17-25%).
4.4 Proteome analysis
The recent advancements in mass spectrometry have allowed rapid progression of
cost effective, high throughput meaningful proteomic studies.188 This study utilised
four prostate epithelial cell lines, namely BPH-1, LNCaP, PC-3 and PNT2C2. BPH-
1 is benign hyperplastic prostatic epithelial cell line obtained during a transurethral
resection and immortalised with SV40 that gives a good indication of benign
uncontrolled growth of prostate tissue.148 The LNCaP cell line obtained from
a human metastatic prostate adenocarcinoma localised to the lymph node has
been a staple of multiple studies of early PCa due to its dependence on androgen
stimulation.146 It has since been found that LNCaP cells are not intrinsically
tumorigenic without the introduction of several external components such as
the extracellular matrix and paracrine-mediated growth factors highlighting the
requirement for several factors to maintain metastatic ability.189,190 PC-3 was
obtained from a prostatic adenocarcinoma metastatic to bones and is a useful
tool for modelling late stage cancer.191 PC-3 also serves as a model for androgen
independent PCa.191 The PNT2C2 cell line, which is a subset of the PNT2 cell
line, was obtained post mortem from a healthy prostate and immortalised with
SV40200. This cell line is often used as a model of the normal prostate epithelium.192
Previous studies have mainly focussed on gene expression and transcript profiles to
identify differences in prostatic conditions.193,194 These provide useful information
on possible causes observed in protein expression changes and add to the knowledge
base of prostatic conditions. However, protein products undergo multiple changes
after transcription and translation and thus these findings may be less informative
then a proteomic approach116.
A total of 3576 proteins were identified in this study and IPAs’ extensive curated
Stellenbosch University  https://scholar.sun.ac.za
4.4. PROTEOME ANALYSIS 75
database was utilised to compare the differences in pathways, upstream regulators
and molecular and cellular functions between the cell lines (table 3.3 - 3.8 and
figure 3.5 -3.7). In all cases the BPH-1, LNCaP and PC-3 cell lines were compared
to the PNT2C2 reference cell line. The aim of these analyses was to determine if
there were any differences in these cell lines, which could be exploited as potential
biomarkers, especially as the current biomarker PSA does not discriminate between
BPH and PCa.
It is perhaps unsurprising that IPA analysis yielded several common traits among
the cell lines since they all essentially share the same origin (prostate epithelial
cells), albeit from different disease states. This trend is clearly observed in the
conserved nature of the pathways, upstream regulators, disease states, molecular
and cellular functions and the assigned GO terms. GO term annotations showed
extensive conservation in biological processing, cellular components and molecular
function. This conservation therefore makes the identification of biomarkers unique
to cancerous or benign conditions a challenge. IPA analysis did, however, identify
specific pathways and upstream regulators upregulated in the LNCaP and PC-3
cell lines, but not the BPH-1 cell line that could potentially be exploited as possible
avenues for biomarker discovery.
The EIF2 signalling, eIF4 and p70S6K signalling, tRNA charging, mTOR
signalling and protein ubiquitination pathways were identified as upregulated in the
three cell lines and are directly responsible for functions such as cell growth, prolif-
eration, RNA post-transcriptional modification, protein synthesis and development.
They act through various mechanisms such as translation initiation and control,
protein recycling and pathway activation in response to stimuli and are critical in
maintaining cell viability, cell growth potential, and proliferation. Interestingly,
mitochondrial pathways and oxidative phosphorylation pathways were shown to be
significantly upregulated in the LNCaP cell line compared to the BPH-1 and PC-3
cell lines. These pathways are responsible for maintaining ATP production and
control of reactive oxygen species (ROS). Mitochondrial dysfunction and oxidative
phosphorylation pathway disruptions may impact on effective ROS neutralisation,
which subsequently results in DNA damage. This may result in and necrosis or
apoptosis but can also result in mutant cellular proliferation. It is well known that
changes in mitochondria function and oxidative phosphorylation have cancerous
effects and in particular ROS have been implicated in carcinogenesis through ox-
idative stress and mitogenic signalling remodelling.195 These modifications allow
increased resistance to apoptosis in a oxidative phosphorylation disrupted low oxy-
gen environment.195 Notably, the remodelling of Adherens Junctions and epithelial
Adherens Junctions pathways that are directly linked to cellular migration were
significantly upregulated in both of the prostate cancer cell lines (LNCaP and PC-3)
compared to the BPH-1 cell line. The Adherens Junctions and epithelial Adherens
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Junctions are specialised sub-apical structures that control cell-cell adhesion and
the remodelling of these junctions results in their dissociation and increases the
migration potential of cells increasing the risk of metastasis. The unique nature
of these pathways that are highly upregulated in the PCa related cell lines may
provide an avenue for reliable biomarker discovery. Previous work on regulation of
Adherens junctions and their effect on PCa previously been investigated by Ramteke
et al. and Knights et al.196,197 Ramteke et al. showed that proteins from exomes
secreted by LNCaP and PC-3 cells under hypoxic conditions were associated with
the remodelling of the epithelial Adherens junctions44. These secreted exomes and
proteins were also shown to induce motility and invasiveness of other näıve LNCaP
and PC-3 cells.196 Knights et al. showed that the deregulation of Adherens junction
genes is positively correlated with progression PCa and that Adherens junction
components such as beta-catenin and E-cadherin, which were also identified in the
LNCaP and PC-3 cell lines during this study, can act as prognostic and diagnostic
biomarkers for PCa45. Exploitation of proteins preferentially involved in these
pathways could therefore act potentially useful candidate biomarkers for PCa.
The core analysis function of IPA can be used to identify the possible disease
states, which are a result of the identified upregulated pathways, upstream regulators
and molecular and cellular functions. Cancer and tumour morphology were two of
the conditions identified which explained the identified changes in all cell lines. A
causal link can be seen between the upregulation of the EIF2 signalling, eIF4 and
p70S6K signalling, tRNA charging, mTOR signalling and protein ubiquitination
pathways and increased protein turnover, cell growth and proliferation which, are
characteristic events associated with tumour and cancer progression.198 The finding
that cancer and tumour morphology were also identified as possible disease states
for BPH-1 further emphasises the similarities between the PCa and BPH and thus
the difficulty in identifying a biomarker which is unique to PCa and not BPH.
Nonetheless, several known curated candidate biomarkers were identified (tables
3.14 and 3.15) in this study. What’s more potentially novel biomarkers not in the
IPA database were also identified (supplementary tables 5.1 - 5.3).
The identification of the known secreted proteins such as PSA and PSMA
validated our approach in identifying new potential promising candidates.153,193
Promising candidates included Armadillo repeat protein deleted in velo-cardio-
facial syndrome (C9JJX6), Ankyrin-3 (Q12955), protein transport protein Sec23B
(Fragment) (Q5F2F8) and Annexin A6 (P08133), which were all identified by IPA
and were found in either LNCaP or PC-3 when considering only extracellular and
membrane bound proteins. Protein LLP homolog (Protein LAPS18-like) (Q9BRT6)
and Cell growth-regulating nucleolar protein (Q9NX58) were identified as common
biomarkers for both LNCaP and PC-3 cell lines and are therefore the two of the
most promising candidates. While Protein LLP homolog (Protein LAPS18-like) is
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a cell permeable protein known to interact with transcriptional machinery such as
RNA polymerase II and TATA binding protein aiding in translation and protein
synthesis, this protein has not been well characterised to date and more work needs
to be done to validate its potential as a biomarker for PCa. The Cell growth-
regulating nucleolar protein was identified as membrane bound or extracellular
protein in this study, a finding which contradicts previous studies which showed
that it was preferentially localised to the nucleus.199 Lishan et al. validated its
subcellular location using indirect immunofluorescence staining which could explain
why it was not detected as membrane bound or the extracellular component.199
Analysis on the gene level has showed the presence of two putative DNA binding
zinc finger domains which it uses to regulate cell growth through sequence specific
binding and transcriptional regulation199 Furthermore, Lishan et al. suggested that
this protein may be involved in cell proliferation and tumourigenesis.199
While the identification of extracellular and membrane bound proteins from
the whole proteome is useful as demonstrated above, an ideal biomarker should
be detectable in serum or urine. The characterisation of the secretome provides
a method which is more likely to lead to the discovery of such proteins and is
essential for the validation of potential candidates.
4.5 Secretome analysis
Secretomics, which is the study of proteins secreted from cells during normal and
altered cellular function has recently come to the forefront of biomarker discovery
for its ability to rapidly identify a large set of proteins that are extracellular to cells
and are therefore possibly non-invasive to obtain in a clinical setting.172 The field of
secretomics combined with advances in bottom up and quantitative proteomics has
provided a powerful approach when identifying novel biomarkers.172 The use of a
bottom up approach has also been linked to incorrect identification of proteins and
therefore must be taken into consideration when deciding on potential candidate
biomarkers.121
As previously mentioned sample optimisation, collection and precipitation was
completed on secretome samples. Unfortunately, due to technical difficulties only a
preliminary analysis of preliminary secretome samples precipitated using ammonium
sulphate was performed. These samples were not optimal due low recovery, which
was later demonstrated and discussed above.
Nonetheless, distinct protein expression profiles were observed. The distribution
of unique proteins across the cell lines (figure 3.13) shows that 3%, 24%, 9%
and 4% of the identified proteins were unique to the BPH-1, LNCaP, PC-3 and
PNT2C2 cell lines, respectively. The subsequent selection of membrane bound and
extracellular proteins further validated the changes in unique protein expression
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and showed that 5%, 17%, 8% and 3% of the identified proteins were unique to
the BPH-1, LNCaP, PC-3 and PNT2C2 cell lines, respectively. The selection of
extracellular and membrane bound protein allowed the identification of several
candidate biomarkers from the IPA database (table 3.17) and identified a number of
novel candidate biomarkers for PCa (supplementary table 5.4 - 5.6). Interestingly,
only a small overlap was observed between the proteome and secretome when
considering membrane and extracellular proteins. This is perhaps not surprising
as the analysis of proteome samples contain significantly more proteins which
may mask the detection of candidate biomarkers. Furthermore, the proteome
samples were washed prior to analysis, so any secreted proteins or loosely bound
membrane proteins may have been removed. This finding therefore demonstrates
the importance of utilising a secretome approach.
Ankyrin-3, Methylosome subunit pICln, Clathrin heavy chain 1, Ubiquitin-like
protein ISG15, Moesin, Spectrin alpha chain non-erythrocytic 1, Spectrin beta chain
non-erythrocytic 1 and DNA FLJ53769, highly similar to Homo sapiens nebulette
(NEBL), transcript variant 2, mRNA were identified as potential biomarkers for
PCa from IPA secretome analysis. Wei et al. previously showed that methylosome
subunit pICln has been linked to PCa through its interaction with certain protein
arginine methyltransferases (PRMT) such as PRMT5, which have been implicated
in tumourigenesis.200 Prescott et al. have shown that Clathrin heavy chain 1 was
upregulated the presence of androgens in the LNCaP cell line and indicated that it
may be involved in the exocytosis of androgen-regulated secretory proteins such as
PSA.201 Kiessling et al. have shown a positive link between ubiquitin-like protein
ISG15 and PCa.202 They showed that it was upregulated in LNCaP cells and further
upregulated in patients who have undergone ablation therapy.202 Chakraborty et al.
have shown that Moesin can be positively correlated to PCa through its interaction
with G protein-coupled receptor kinases (GRK) such GRK5 is known to increase
the migration and invasion of PCa cells.203 Khan et al. revealed that Spectrin
alpha chain non-erythrocytic 1 was upregulated in PCa cells compared to benign
tissue.204 Zhixing et al. showed that there was a negative correlation between
Spectrin beta chain non-erythrocytic 1 and activating transcription factor 4 (ATF4
which has previously been implicated in PCa.205 Monitoring the loss of Spectrin
beta chain non-erythrocytic 1 could allow the monitoring of PCa progression.205
Wakamatsu et al. has identified the cDNA FLJ53769, highly similar to Homo
sapiens nebulette (NEBL), transcript variant 2, mRNA but only at the transcript
level for PCa.206
Ankyrin-3 is potentially the most promising candidate biomarker for PCa
identified in this study as it was identified by IPA to be specific to the LNCaP
proteome and secretome and was confirmed as LNCaP specific by our MS analysis
with a high significance in both cases. Its main cellular functions have been
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linked to cell motility, activation, proliferation, contact, and the maintenance of
specialised membrane domains.207 It has been identified at the protein level and
implicated in multiple cancer types including PCa by The Human Protein Atlas
group (www.proteinatlas.org). Its high upregulation, subcellular location and its
unique association to the LNCaP cell line make it a potentially useful biomarker
for the relatively early diagnosis of PCa.
4.6 Conclusion
The proteomic-based approach utilised in this study yielded multiple previously
identified and new proteins that could be used as potential biomarkers for PCa.
The analysis of the proteome allowed for a deeper understanding of the regulation
of the cell based models in terms of preferential pathways, upstream regulators,
and molecular and cellular processes. This study has shown that a secretom-
ics based approach provides a simple and high throughput means of identifying
multiple potential extracellular candidate biomarkers. As only the preliminary
secretome data was available the possible candidate biomarkers would still need
to be adequately validated before any further assumptions can be made on their
potential. Furthermore, only proteins, which were found to be membrane bound or
extracellular, were selected as potential candidate biomarkers. While this approach
reduces the analysis space and increases the likelihood of identifying non-invasive
biomarkers it relies on accurately assigned GO terms. Therefore by applying this
type of filter several potential biomarkers may be lost. This preliminary secretome
investigation validates a proof of concept for the identification of novel biomarkers
for prostate cancer using a proteomic approach.
4.7 Future studies
Numerous future applications of this study are possible. Weaknesses in this study
such as the presence of intracellular proteins need to be reduced further possibly by
further optimisation of cell culture techniques or through the use of alternate cell
culture methods such as 3D cell culture. The implications of identifying biomarkers
in secretome cell culture studies is also only the first step in identifying novel tests
for PCa, extensive upscaling needs to be done to confirm the proteins identified are
present only in the cell lines observed and not false positive identifications from
mass spectrometry. This study acts as a foundation for further studies utilising
primary culture xenografts, patient sera and finally large-scale patient studies to
confirm the specificity, sensitivity and efficacy of identified biomarkers.
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Addenda
Supplementary tables
Table S1: Proteins identified during tandem mass spectrometry of the LNCaP
cell line whole cell samples containing extracellular or membrane bound GO term
annotations obtained from the NCBI database that may act as candidate biomarkers
for PCa.




Rab GDP dissociation inhibitor alpha (Rab GDI alpha)








Lipopolysaccharide-responsive and beige-like anchor protein






N-sulphoglucosamine sulphohydrolase (EC 3.10.1.1)
(Sulfoglucosamine sulfamidase) (Sulphamidase)
SGSH HSS
P53367 ARFP1 HUMAN Arfaptin-1 (ADP-ribosylation factor-interacting protein 1) ARFIP1
P53985 MOT1 HUMAN
Monocarboxylate transporter 1 (MCT 1) (Solute carrier





(N-acetyl-alpha-glucosaminidase) (NAG) [Cleaved into:
Alpha-N-acetylglucosaminidase 82 kDa form;




Delta-1-pyrroline-5-carboxylate synthase (P5CS) (Aldehyde
dehydrogenase family 18 member A1) [Includes: Glutamate
5-kinase (GK) (EC 2.7.2.11) (Gamma-glutamyl kinase);








NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 6 (Complex I-B14) (CI-B14) (LYR motif-containing
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DNA repair protein complementing XP-C cells (Xeroderma




Dihydroorotate dehydrogenase (quinone), mitochondrial
(DHOdehase) (EC 1.3.5.2) (Dihydroorotate oxidase)
DHODH
Q05682 CALD1 HUMAN Caldesmon (CDM)
CALD1
CAD CDM
Q12955 ANK3 HUMAN Ankyrin-3 (ANK-3) (Ankyrin-G) ANK3
Q13505 MTX1 HUMAN





Q13823 NOG2 HUMAN Nucleolar GTP-binding protein 2 (Autoantigen NGP-1)
GNL2
NGP1
Q14353 GAMT HUMAN Guanidinoacetate N-methyltransferase (EC 2.1.1.2) GAMT
Q16134 ETFD HUMAN
Electron transfer flavoprotein-ubiquinone oxidoreductase,





NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 9, mitochondrial (Complex I-39kD) (CI-39kD)









Brefeldin A-inhibited guanine nucleotide-exchange protein 3





Q5VZR0 Q5VZR0 HUMAN Golgi-associated plant pathogenesis-related protein 1 GLIPR2
Q6YN16 HSDL2 HUMAN
Hydroxysteroid dehydrogenase-like protein 2 (EC 1.-.-.-)





Probable hydrolase PNKD (EC 3.-.-.-) (Myofibrillogenesis
regulator 1) (MR-1) (Paroxysmal nonkinesiogenic dyskinesia













39S ribosomal protein L30, mitochondrial (L30mt)







Estradiol 17-beta-dehydrogenase 8 (EC 1.1.1.62)
(17-beta-hydroxysteroid dehydrogenase 8) (17-beta-HSD 8)
(3-ketoacyl-[acyl-carrier-protein] reductase alpha subunit)
(KAR alpha subunit) (3-oxoacyl-[acyl-carrier-protein]
reductase) (EC 1.1.1.-) (Protein Ke6) (Ke-6) (Really
interesting new gene 2 protein) (Short chain
dehydrogenase/reductase family 30C member 1)







Endoplasmic reticulum-Golgi intermediate compartment











Q96ED9 HOOK2 HUMAN Protein Hook homolog 2 (h-hook2) (hHK2) HOOK2
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Entry Entry name Protein names
Gene
names





DnaJ homolog subfamily C member 2 (M-phase
phosphoprotein 11) (Zuotin-related factor 1) [Cleaved into:







Growth/differentiation factor 15 (GDF-15) (Macrophage
inhibitory cytokine 1) (MIC-1) (NSAID-activated gene 1
protein) (NAG-1) (NSAID-regulated gene 1 protein)
(NRG-1) (Placental TGF-beta) (Placental bone



















28S ribosomal protein S26, mitochondrial (MRP-S26)






39S ribosomal protein L37, mitochondrial (L37mt)







Ankyrin repeat and zinc finger domain-containing protein 1








Acyl-coenzyme A thioesterase 13 (Acyl-CoA thioesterase 13)
(EC 3.1.2.-) (Thioesterase superfamily member 2) [Cleaved







Xaa-Pro aminopeptidase 1 (EC 3.4.11.9) (Aminoacylproline
aminopeptidase) (Cytosolic aminopeptidase P) (Soluble
aminopeptidase P) (sAmp) (X-Pro aminopeptidase 1)

























NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 12 (13 kDa differentiation-associated protein)











Proteasome maturation protein (Proteassemblin) (Protein
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Table S2: Proteins identified during tandem mass spectrometry of the PC-3 cell
line whole cell samples containing extracellular or membrane bound GO term
annotations obtained from the NCBI database that may act as candidate biomarkers
for PCa. Protein and gene information was obtained from the UniProt database.
Entry Entry name Protein names
Gene
names
E7ESA6 E7ESA6 HUMAN Focal adhesion kinase 1 PTK2
E7EV59 E7EV59 HUMAN V-type proton ATPase subunit C 1 ATP6V1C1
E9PGC5 E9PGC5 HUMAN Receptor-type tyrosine-protein phosphatase kappa PTPRK
F5GX39 F5GX39 HUMAN Transmembrane emp24 domain-containing protein 2 TMED2
F5H442 F5H442 HUMAN Tumour susceptibility gene 101 protein TSG101
F5H459 F5H459 HUMAN AP-3 complex subunit sigma-1 AP3S1
G3XAL9 G3XAL9 HUMAN
Solute carrier family 12 (Sodium/potassium/chloride
transporters), member 2, isoform CRA a (Solute carrier




DCN1-like protein (Defective in cullin neddylation protein
1-like protein) (Fragment)
DCUN1D5
H0YDT8 H0YDT8 HUMAN ER membrane protein complex subunit 7 (Fragment) EMC7
H3BRB1 H3BRB1 HUMAN Uncharacterized protein N/A
K7EL21 K7EL21 HUMAN Calcyphosin (Calcyphosine, isoform CRA b)
CAPS
hCG 23051
O00178 GTPB1 HUMAN GTP-binding protein 1 (G-protein 1) (GP-1) (GP1) GTPBP1
O00231 PSD11 HUMAN
26S proteasome non-ATPase regulatory subunit 11 (26S
proteasome regulatory subunit RPN6) (26S proteasome
regulatory subunit S9) (26S proteasome regulatory subunit
p44.5)
PSMD11





Actin-related protein 2/3 complex subunit 3 (Arp2/3








Rho-associated protein kinase 2 (EC 2.7.11.1) (Rho kinase 2)
(Rho-associated, coiled-coil-containing protein kinase 2)









Immunoglobulin lambda variable 1-44 (Ig lambda chain V-I
region MEM) (Ig lambda chain V-I region VOR)
IGLV1-44
P05556 ITB1 HUMAN
Integrin beta-1 (Fibronectin receptor subunit beta)











Cytochrome c1, heme protein, mitochondrial (Complex III
subunit 4) (Complex III subunit IV) (Cytochrome b-c1
complex subunit 4) (Ubiquinol-cytochrome-c reductase
complex cytochrome c1 subunit) (Cytochrome c-1)
CYC1
P09467 F16P1 HUMAN
Fructose-1,6-bisphosphatase 1 (FBPase 1) (EC 3.1.3.11)





Fatty acid-binding protein, adipocyte (Adipocyte
lipid-binding protein) (ALBP) (Adipocyte-type fatty
acid-binding protein) (A-FABP) (AFABP) (Fatty
acid-binding protein 4)
FABP4
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Entry Entry name Protein names
Gene
names





(15-PGDH) (EC 1.1.1.141) (Prostaglandin dehydrogenase 1)





E3 ubiquitin-protein ligase CBL (EC 6.3.2.-) (Casitas
B-lineage lymphoma proto-oncogene) (Proto-oncogene c-Cbl)




ATP synthase F(0) complex subunit B1, mitochondrial (ATP
synthase proton-transporting mitochondrial F(0) complex
subunit B1) (ATP synthase subunit b) (ATPase subunit b)
ATP5F1
P40123 CAP2 HUMAN Adenylyl cyclase-associated protein 2 (CAP 2) CAP2
P45877 PPIC HUMAN
Peptidyl-prolyl cis-trans isomerase C (PPIase C) (EC 5.2.1.8)




Glycogen synthase kinase-3 beta (GSK-3 beta) (EC
2.7.11.26) (Serine/threonine-protein kinase GSK3B) (EC
2.7.11.1)
GSK3B
P50552 VASP HUMAN Vasodilator-stimulated phosphoprotein (VASP) VASP






S-phase kinase-associated protein 1
(Cyclin-A/CDK2-associated protein p19) (p19A) (Organ of
Corti protein 2) (OCP-2) (Organ of Corti protein II)
(OCP-II) (RNA polymerase II elongation factor-like protein)















Integrin-linked protein kinase (EC 2.7.11.1) (59 kDa
serine/threonine-protein kinase) (ILK-1) (ILK-2) (p59ILK)
ILK ILK1
ILK2













Q5JXI8 Q5JXI8 HUMAN Four and a half LIM domains protein 1 (Fragment) FHL1
Q5QPE1 Q5QPE1 HUMAN Protein transport protein Sec23B (Fragment) SEC23B




Multiple coagulation factor deficiency protein 2 (Neural stem










Receptor-type tyrosine-protein phosphatase U (R-PTP-U)
(EC 3.1.3.48) (Pancreatic carcinoma phosphatase 2) (PCP-2)
(Protein-tyrosine phosphatase J) (PTP-J) (hPTP-J)
(Protein-tyrosine phosphatase pi) (PTP pi) (Protein-tyrosine
phosphatase receptor omicron) (PTP-RO) (Receptor-type




Q96DG6 CMBL HUMAN Carboxymethylenebutenolidase homolog (EC 3.1.-.-) CMBL
Q96GD0 PLPP HUMAN
Pyridoxal phosphate phosphatase (PLP phosphatase) (EC




Q99805 TM9S2 HUMAN Transmembrane 9 superfamily member 2 (p76) TM9SF2
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Latexin (Endogenous carboxypeptidase inhibitor) (ECI)
(Protein MUM) (Tissue carboxypeptidase inhibitor) (TCI)
LXN
Q9BXS5 AP1M1 HUMAN
AP-1 complex subunit mu-1 (AP-mu chain family member
mu1A) (Adaptor protein complex AP-1 subunit mu-1)
(Adaptor-related protein complex 1 subunit mu-1) (Clathrin
assembly protein complex 1 mu-1 medium chain 1) (Clathrin
coat assembly protein AP47) (Clathrin coat-associated
protein AP47) (Golgi adaptor HA1/AP1 adaptin mu-1
subunit) (Mu-adaptin 1) (Mu1A-adaptin)
AP1M1
CLTNM
Q9H089 LSG1 HUMAN Large subunit GTPase 1 homolog (hLsg1) (EC 3.6.1.-) LSG1
Q9H0U4 RAB1B HUMAN Ras-related protein Rab-1B RAB1B
Q9H299 SH3L3 HUMAN
SH3 domain-binding glutamic acid-rich-like protein 3 (SH3








Phosphatidylinositide phosphatase SAC1 (EC 3.1.3.-)




Serine/threonine-protein kinase 26 (EC 2.7.11.1) (MST3 and
SOK1-related kinase) (Mammalian STE20-like protein






AP-3 complex subunit mu-1 (AP-3 adaptor complex mu3A
subunit) (Adaptor-related protein complex 3 subunit mu-1)
(Mu-adaptin 3A) (Mu3A-adaptin)
AP3M1




Q9Y4G6 TLN2 HUMAN Talin-2
TLN2
KIAA0320
Table S3: Proteins identified during tandem mass spectrometry of the LNCaP and
PC-3 cell lines whole cell samples containing extracellular or membrane bound GO
term annotations obtained from the NCBI database that may act as candidate
biomarkers for PCa. Protein and gene information was obtained from the UniProt
database.




Voltage-dependent anion-selective channel protein 1
(Fragment)
VDAC1
E7EVA0 E7EVA0 HUMAN Microtubule-associated protein MAP4
F8W7Q4 F8W7Q4 HUMAN Protein FAM162A FAM162A
O43633 CHM2A HUMAN
Charged multivesicular body protein 2a
(Chromatin-modifying protein 2a) (CHMP2a) (Putative
breast adenocarcinoma marker BC-2) (Vacuolar protein





Enoyl-CoA delta isomerase 2, mitochondrial (EC 5.3.3.8)
(DRS-1) (Delta(3),delta(2)-enoyl-CoA isomerase)
(D3,D2-enoyl-CoA isomerase) (Diazepam-binding
inhibitor-related protein 1) (DBI-related protein 1)
(Dodecenoyl-CoA isomerase) (Hepatocellular
carcinoma-associated antigen 88) (Peroxisomal
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Protein Wiz (Widely-interspaced zinc finger-containing
protein) (Zinc finger protein 803)
WIZ
ZNF803




Immunoglobulin kappa variable 1-39 (Ig kappa chain V-I
region DEE) (Ig kappa chain V-I region Hau) (Ig kappa
chain V-I region Mev) (Ig kappa chain V-I region OU) (Ig
kappa chain V-I region Walker)
IGKV1-39
P04350 TBB4A HUMAN






Annexin A6 (67 kDa calelectrin) (Annexin VI) (Annexin-6)
(Calphobindin-II) (CPB-II) (Chromobindin-20) (Lipocortin




Lysosomal alpha-glucosidase (EC 3.2.1.20) (Acid maltase)
(Aglucosidase alfa) [Cleaved into: 76 kDa lysosomal
alpha-glucosidase; 70 kDa lysosomal alpha-glucosidase]
GAA
P12004 PCNA HUMAN Proliferating cell nuclear antigen (PCNA) (Cyclin) PCNA
P20618 PSB1 HUMAN
Proteasome subunit beta type-1 (EC 3.4.25.1) (Macropain
subunit C5) (Multicatalytic endopeptidase complex subunit




60S ribosomal protein L10 (Laminin receptor homolog)





Mitogen-activated protein kinase 1 (MAP kinase 1) (MAPK
1) (EC 2.7.11.24) (ERT1) (Extracellular signal-regulated
kinase 2) (ERK-2) (MAP kinase isoform p42) (p42-MAPK)







Peroxiredoxin-2 (EC 1.11.1.15) (Natural killer cell-enhancing
factor B) (NKEF-B) (PRP) (Thiol-specific antioxidant
protein) (TSA) (Thioredoxin peroxidase 1)




P35080 PROF2 HUMAN Profilin-2 (Profilin II) PFN2
P40429 RL13A HUMAN 60S ribosomal protein L13a (23 kDa highly basic protein) RPL13A
P56181 NDUV3 HUMAN
NADH dehydrogenase [ubiquinone] flavoprotein 3,
mitochondrial (Complex I-9kD) (CI-9kD)




Peptidyl-prolyl cis-trans isomerase FKBP1A (PPIase
FKBP1A) (EC 5.2.1.8) (12 kDa FK506-binding protein) (12
kDa FKBP) (FKBP-12) (Calstabin-1) (FK506-binding















Q13596 SNX1 HUMAN Sorting nexin-1 SNX1
Q14527 HLTF HUMAN
Helicase-like transcription factor (EC 3.6.4.-) (EC 6.3.2.-)
(DNA-binding protein/plasminogen activator inhibitor 1
regulator) (HIP116) (RING finger protein 80)
(SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily A member 3) (Sucrose








Syntaxin-binding protein 2 (Protein unc-18 homolog 2)
(Unc18-2) (Protein unc-18 homolog B) (Unc-18B)
STXBP2
UNC18B
Q5QNZ2 Q5QNZ2 HUMAN ATP synthase F(0) complex subunit B1, mitochondrial ATP5F1
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mitochondrial (EC 3.1.3.16) (Bcl-XL-binding protein v68)
(Phosphoglycerate mutase family member 5)
PGAM5
Q99798 ACON HUMAN





1.13.11.54) (Acireductone dioxygenase (Fe(2+)-requiring))
(ARD) (Fe-ARD) (Membrane-type 1 matrix
metalloproteinase cytoplasmic tail-binding protein 1)






DnaJ homolog subfamily B member 11 (APOBEC1-binding
protein 2) (ABBP-2) (DnaJ protein homolog 9)
(ER-associated DNAJ) (ER-associated Hsp40 co-chaperone)
(Endoplasmic reticulum DNA J domain-containing protein 3)
(ER-resident protein ERdj3) (ERdj3) (ERj3p) (HEDJ)









Phenylalanine–tRNA ligase alpha subunit (EC 6.1.1.20)







Hypoxia up-regulated protein 1 (150 kDa oxygen-regulated



















Table S4: Extracellular and membrane bound proteins unique to the LNCaP cell
line identified during mass spectrometry of preliminary secretome samples (n=1).








Cadherin-1 (CAM 120/80) (Epithelial cadherin) (E-cadherin)











Serine/threonine-protein phosphatase 2A catalytic subunit
beta isoform (PP2A-beta) (EC 3.1.3.16)
PPP2CB
Q07954 LRP1 HUMAN
Prolow-density lipoprotein receptor-related protein 1
(LRP-1) (Alpha-2-macroglobulin receptor) (A2MR)
(Apolipoprotein E receptor) (APOER) (CD antigen CD91)
[Cleaved into: Low-density lipoprotein receptor-related
protein 1 85 kDa subunit (LRP-85); Low-density lipoprotein
receptor-related protein 1 515 kDa subunit (LRP-515);
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Serine/threonine-protein kinase D1 (EC 2.7.11.13) (Protein







Triokinase/FMN cyclase (Bifunctional ATP-dependent
dihydroxyacetone kinase/FAD-AMP lyase (cyclizing))
[Includes: ATP-dependent dihydroxyacetone kinase (DHA
kinase) (EC 2.7.1.28) (EC 2.7.1.29) (Glycerone kinase)
(Triokinase) (Triose kinase); FAD-AMP lyase (cyclizing) (EC





Sec1 family domain-containing protein 1 (SLY1 homolog)






Table S5: Extracellular and membrane bound proteins unique to the PC-3 cell line
identified during mass spectrometry of preliminary secretome samples (n=1).
Entry Entry name Protein names
Gene
names
E9PK47 E9PK47 HUMAN Alpha-1,4 glucan phosphorylase (EC 2.4.1.1) PYGL
Q14533 KRT81 HUMAN
Keratin, type II cuticular Hb1 (Hair keratin K2.9) (Keratin,
hair, basic, 1) (Keratin-81) (K81) (Metastatic lymph node
137 gene protein) (MLN 137) (Type II hair keratin Hb1)





Protein ABHD14B (EC 3.-.-.-) (Alpha/beta hydrolase
domain-containing protein 14B) (Abhydrolase
domain-containing protein 14B) (CCG1-interacting factor B)
ABHD14B
CIB
Table S6: Extracellular and membrane bound proteins common to the LNCaP
and PC-3 cell lines identified during mass spectrometry of preliminary secretome
samples (n=1).











Cysteine and glycine-rich protein 1 (Cysteine-rich protein 1)




P84077 ARF1 HUMAN ADP-ribosylation factor 1 ARF1
Q13200 PSMD2 HUMAN
26S proteasome non-ATPase regulatory subunit 2 (26S
proteasome regulatory subunit RPN1) (26S proteasome
regulatory subunit S2) (26S proteasome subunit p97)
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